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Abstract
ABSTRACT
Alzheimer’s disease (AD) is a form of progressive dementia which affects many of the world’s 
population. AD patients show a decrease in cognitive function, loss of memory and at a later stage, 
decreasing physical activity. So far, the only definite diagnosis of AD is still based on post-mortem 
demonstration of extensive cell loss, and the presence of amyloid plaques and neurofibrillary 
tangles in the brains of sufferers. Cleavage of the amyloid precursor protein (APP) by p-secretase 
results in the production of the C-terminal fragment (CTF) of APP, C99, which is in turn cleaved 
by the y-secretase. This cleavage event produces the Ap peptides, which aggregate to form the 
amyloid deposits seen in the brains of AD patients. y-Secretase has eluded identification for many 
years, however it has been shown in various eukaryotic systems that it is a highly stable protein 
complex of high relative molecular mass consisting of the membrane proteins PS-1, Nicastrin 
(NicA), Pen-2 and Aph-1.
This thesis shows that E. coli represents a simple and efficient system that can be used to analyse 
human membrane proteins, and in this case to verify that PS-1, NicA, Pen-2 and Aph-1 are the 
minimal components required for y-secretase activity. Components of the y-secretase complex were 
successfully cloned and expressed in E. coli and their topologies in the bacterial membrane were 
studied in vivo by a genetic approach which involves generating hybrids of the target membrane 
proteins to alkaline phosphatase (PhoA). In addition, initial experiments carried out with the aim of 
reconstituting y-secretase activity in E. coli are described. Furthermore, the E. coli two hybrid 
system was successfully utilised to unveil interactions between the y-secretase components and to 
isolate candidate interaction partners of PS-1 and its gain of function mutant PS-lAexon9. Thus E. 
coli can be used as a model system to aid our understanding of the processes involved in AD.
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1 GENERAL INTRODUCTION
1.1 Alzheimer9s disease
1.1.1 Introduction
Alzheimer’s disease (AD) is the most widespread form of progressive dementia worldwide as it 
affects about 17-25 million people. In western countries AD is regarded as the fourth leading cause 
of death after heart diseases, cancer and stroke. The incidence of AD increases with age, and it 
doubles every five years beyond the age of 65. However, diagnosis of AD is limited to the 
exclusion of other diseases and the only definite diagnosis to date is still based on post mortem 
histopathological demonstration of amyloid plaques and neurofibrillary tangles (Figure 1.1) (Czech 
et al., 2000).
AD is a brain disease which especially affects the temporal and parietal cortex, hippocampus, and 
amygdala. AD patients suffer from loss of memory, deterioration in cognitive function, and 
eventually decreasing physical abilities (Czech et al., 2000). The neuropathology of AD is defined 
by extensive neuronal cell loss and by the presence of neurofibrillary tangles and amyloid plaques 
in the brains of sufferers. Neurofibrillary tangles are intracellular protein aggregates in the form of 
paired helical filaments, mostly consisting of the microtubule associated protein tau (Goedert et al., 
1992). Amyloid plaques are extracellular protein aggregates composed in the majority of the 13- 
sheet structure, amyloid p-peptide (Ap) (Glenner and Wong, 1984; Masters et al., 1985b). Ap is 
deposited in the brain parenchyma and in the majority of AD cases, in the wall of cerebral blood 
vessels (Masters et al., 1985a).
14
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Norm al A lzh eim er's
Neurofibrillar 
ta n g le s  .
A m yloid
p la q u e s
N euron
Figure (1.1) Diagramatic representation comparing neural tissue from a healthy individual,
to that of one suffering from AD.
Neurofibrillary tangles are shown as intracellular protein aggregates in the form o f helical filaments and amyloid
plaques are extracellular protein aggregates. Taken from: http://www.ahaf.org/alzdis/about/pIaques_tangles.jpg
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1.1.2 The genetics of AD
There are two types of AD. Most cases of AD are sporadic with no obvious inheritance pattern and 
late age of onset (65 years or over). However, there are a few autosomal dominant cases of familial 
AD (FAD) where the age of onset is much lower (St George-Hyslop, 1998). The major cause of 
FAD is mutations in the presenilin-1 (PS-1) gene on chromosome 14. There are more than 50 
missense mutations identified to date, localised throughout the protein with hot spots more 
predisposed for pathogenic mutations, especially in the transmembrane segments and the region 
from residue 260 to 290 encoded by exon 8 (Czech et al., 2000). Some mutations have also been 
localised to the PS-2 gene on chromosome 1, and the majority of PS mutations have been found to 
occur in residues conserved in PS-1 (Rogaev et al., 1995). Thus, all PS mutations are missence 
mutations, except for the mutation of a splice acceptor site resulting in the deletion of exon 9 (delta 
exon 9 mutation).
Down’s syndrome patients often develop AD by the age of 50. The APP gene was mapped to 
chromosome 21 (Goate et al., 1991) and data that shows increased expression of APP in the brains 
of Down’s syndrome patients is available (Czech et al., 2000). This led to the discovery of several 
rare missense mutations within the APP gene which are located within or close to the AP sequence. 
Examples are the ‘Dutch’ mutation (E693Q) which causes a structural change in Ap, thus 
accelerating the rate of fibril formation (Levy et al., 1990; Wisniewski et al., 1991), the ‘Flemish’ 
mutation (A692G) which alters y-secretase activity resulting in an increase of Ap secretion (Haass 
et al., 1994) and the ‘Swedish’ mutation (KM670-671NL) which promotes APP cleavage by p- 
secretase (Vassar et al., 1999) also resulting in higher levels of Ap produced (See section 1.3.2).
The apolipoprotein E4 allele (apoE4) was found to considerably increase susceptibility for sporadic 
and familial AD (Strittmatter et al., 1993). Apolipoprotein is a plasma membrane protein involved
16
Chapter (1) General introduction
in cholesterol transport (Mahley, 1988). It is produced and secreted in the central nervous system 
by astrocytes (Boyles et al., 1985; Ignatius et al., 1986; Pitas et al., 1987). Its synthesis is increased 
following injury and it is implicated in the growth and repair of the nervous system during 
development or after injury (Boyles et al., 1989; Ignatius et al., 1986).
The risk of AD increases with the dose of the ApoE4 allele, but the ApoE2 allele appears to have 
protective properties (Corder et al., 1994; Corder et al., 1993). The ApoE genotype influences the 
onset of AD in patients with Down-syndrome and in those with APP mutations but not in families 
with presenilin mutations (Bales et al., 1997; Lendon et al., 1997). ApoE is thought to have a role 
in the aggregation and/or clearance of Ap in the brain (Bales et al., 1997).
1,2 The amyloid precursor protein (APP)
APP is a type I transmembrane glycoprotein, proteolytic cleavage of which, produces the amyloid 
peptide (Ap), which forms the major component of the extracellular amyloid deposits in AD (Kang 
et al., 1987). The Ap region of APP consists of 40-42 amino acid residues, located partly within the 
ectodomain and partly within the transmembrane domain of APP (Figure 1.2) (Kang et al., 1987). 
Proteolytic cleavage of APP is carried out by a-, p- and y-secretases.
17
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NH2
APP
ctr cleavage
P- cleavage 
a-
Periplasm
Cytoplasmic
membrane
Cytoplasm
COOH
Figure (1.2) Schematic representation of APP.
The figure shows the APP membrane protein, including the position o f  Ap sequence within the protein and the a-,
and y-secretase cleavage sites.
APP comprises a group of polypeptides whose heterogeneity arises from both alternative splicing 
and posttranslational processing, including the addition of N- and O- linked sugars, phosphate and 
sulphate to the protein. 751- and 770-amino acid splice forms of APP are expressed in non- 
neuronal cells, however neurons express a more abundant 695-residue isoform. The difference 
between the 751/770- and 695-residue forms is the presence in the former of a 56 amino acid exon 
that encodes a region homologous to the Kunitz-type serine protease inhibitor motif, suggesting one 
of the functions of the longer APP isoforms. Certainly, 751/770 forms of APP present in human 
platelets inhibit the factor XIa serine protease in the coagulation cascade (Smith et al., 1990). APP 
is expressed in cells and tissues throughout the body, which raises the question of why substantial, 
clinically important Ap deposition occurs only in the brain. The APP sequence has been highly 
conserved during evolution in mammals and close homologues were found in D. melanogaster and 
C. elegans, although those lack the Ap sequence (Selkoe, 1998).
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Processing of APP by the p-secretase results in the production of AP and a C-terminal fragment 
(CTF) of 57 or 59 residues. This C-terminal fragment is thought to be involved in signaling as is 
found in the nucleus (Cupers et al., 2001; Gao and Pimplikar, 2001) where it interacts with a 
transcriptionally active complex containing the nuclear adaptor protein Fe65 and the histone 
deacetyltransferase (Cao and Sudhof, 2001; Kimberly et al., 2001). This complex targets, for 
example, the KAI1 promoter (Baek et al., 2002). As KAI1 is a cell surface molecule, it interacts 
with plasma membrane receptors and functions as a tumour metastasis suppressor (Maecker et al., 
1997). However, a recent study questions whether the C-terminal APP fragment has to be 
translocated to the nucleus or if it might interact and activate Fe65 while it is still associated with 
the membrane (Cao and Sudhof, 2004). This highlights the need for more work to fully understand 
how APP fragments activate transcription.
It was shown that the axonal transport of APP in neurons is mediated by direct binding of APP to 
the kinesin light chain subunit of kinesin-I, a microtubule motor protein (Kamal et al., 2000). 
Recent experiments by Kamal and co-workers (Kamal et al., 2001) have indicated that APP 
functions as a kinesin-I membrane receptor, mediating the axonal transport of y-secretase and 
presenilin 1, and that the processing of APP to Ap by secretases can occur in an axonal membrane 
compartment transported by kinesin-I.
1.3 The secretases and APP cleavage
1.3.1 The a-secretase pathway
a-Secretase cleaves APP on the C-terminal side of residue 16 of the Ap sequence, which generates 
an 83-residue C-terminal fragment, C83 (Esch et al., 1990). Cleavage of APP by a-secretase 
destroys the Ap sequence, and therefore it is generally thought that the a-secretase pathway 
reduces amyloid plaque formation, however this has not been indisputably proven (Nunan and
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Small, 2000). Furthermore, the C-terminally truncated form of APP released by a-secretase may 
have trophic actions which could oppose the neurotoxic effects of aggregated Ap (Mok et al., 
2000).
The precise subcellular localisation of the a-secretase is unknown, but the trans-Golgi has been 
suggested as one of the sites of a-secretase cleavage (Nunan and Small, 2000). An explanation for 
the uncertainty about the localisation of a-secretase is that there may be more than one enzyme 
(Nunan and Small, 2000). a-Secretase activity has constitutive and regulated components. The 
constitutive activity has not yet been identified, but the regulated activity seems to be under the 
control of protein kinase C (PKC) (Sinha et al., 1999).
Two members of the ADAM (a disintegrin and metalloprotease) family, tumour necrosis factor-a 
(TNFa)-converting enzyme (TACE or ADAM-17) and ADAM-10, are candidate a-secretases 
(Nunan and Small, 2000). TACE cleaves pro-TNFa, releasing the extracellular domain (TNFa) in 
a similar manner to APP cleavage (Nunan and Small, 2000). The inhibition or knockout of TACE 
decreases the release of the a-secretase cleaved product aAPP (Buxbaum et al., 1998b). However, 
cells deficient in TACE still have a residual a-secretase activity (Buxbaum et al., 1998) and 
therefore, TACE may play a role in regulated PKC-dependent a-secretion. Over-expression of 
ADAM-10 increased a-secretase cleavage of APP, while a dominant negative form of ADAM-10 
with a point mutation in the zinc-binding site was found to inhibit basal and stimulated a-secretase 
activity, but did not totally abolish aAPP production (Lammich et al., 1999). ADAM-10 exists only 
in a proenzyme (inactive) form in the Golgi, but becomes activated at the plasma membrane 
(Lammich et al., 1999). Therefore, TACE and ADAM-10 were both thought to be a-secretases.
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It is likely that several proteases contribute to a-secretase activity, and therefore it may be difficult 
to regulate APP processing pharmacologically through this pathway. However, most studies aimed 
at developing inhibitors of Ap production are focused on the two enzymes directly responsible for 
cleaving Ap from APP, that is p- and y-secretase (Nunan and Small, 2000).
1.3.2 The P-secretase pathway
BACE (p site APP cleaving enzyme) or Asp2 has been identified as the p-secretase (Hussain et al., 
1999; Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). It is an unusual 
member of the pepsin family of aspartyl proteases, which has an N-terminal catalytic domain 
containing two important aspartate residues, a transmembrane domain (17 residues) and a short C- 
terminal cytoplasmic tail (Vassar et al., 1999). BACE contains four potential N-linked 
glycosylation sites and a pro-peptide sequence at the N-terminus. In the cell, BACE is expressed 
initially as a pre-proprotein, and then processed to its mature form in the Golgi apparatus (Haniu et 
al., 2000). BACE possesses many of the features of p-secretase including full-length cleavage of 
APP at Aspl of the Ap sequence and also at Glul 1, which is an alternative cleavage site (Vassar et 
al., 1999). Additionally, the Swedish mutation is known to promote cleavage of APP at Aspl by 
BACE. Furthermore, BACE is co-expressed with APP in many regions of the brain, particularly in 
neurons, and has a subcellular distribution similar to that of the observed activity for p-secretase 
(Vassar et al., 1999).
1.3.3 The y-secretase pathway
The final step in the production of Ap is the cleavage of the APP C99 fragment by y-secretase. The 
exact position of cleavage by y-secretase is critical for the development of AD (Nunan and Small, 
2000). Production of the more amyloidogenic long Ap species by cleavage adjacent to the residues
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42 or 43 is strongly associated with disease pathogenesis (Scheuner et al., 1996; Small and 
McLean, 1999).
Before the y-secretase complex was identified, PS-1 and PS-2 were two candidate y-secretases 
(Nunan and Small, 2000). A knockout of both PS-1 and PS-2 completely inhibited all y-secretase 
activity (Herreman et al., 2000) which led to the conclusion that presenilins are required for y- 
secretase activity. Furthermore, presenilins are localised to subcellular compartments known to be 
the sites of y-secretase processing (Hartmann et al., 1997). Subcellular and fractionation 
experiments have shown that PS and y-secretase co-purify as a high molecular weight complex (Li 
et al., 2000a). In addition, y-secretase inhibitors can affinity-label PS subunits (Esler et al., 2000; Li 
et al., 2000b). Thus, it was thought that even if the y-secretase is not identical to the presenilins, 
then the protease activity is at least intimately associated with presenilins in vivo because both 
presenilins have been reported to bind to APP (Weidemann et al., 1997; Xia et al., 1997).
As a result of inhibitor studies, y-secretase was thought to be an aspartyl protease (Wolfe et al., 
1999a). Wolfe and co-workers (Wolfe et al., 1999b), found that mutation of Asp257 and Asp385 in 
the transmembrane domain of PS-1 inhibits y-secretase activity. They suggested that the two Asp 
residues in PS-1 form part of an active catalytic site. However in contrast to this idea, Capell and 
co-workers (Capell et al., 2000), found that PS-1 mutants lacking Asp257 secrete significant 
amounts of Ap. However, PS was never shown to have protease activity, so it was suggested that it 
could simply be a regulatory subunit of y-secretase, or a protein that is somehow involved in the 
trafficking of proteins targeted to y-secretase (Nunan and Small, 2000).
Recently, regulated intamembaneous proteolysis (RIP) has been described which is a mechanism 
very similar to the y-secretase cleavage of APP. RIP involves the cleavage of transmembrane
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proteins within the plane of the membrane to liberate cytosolic fragments which can then enter the 
nucleus to control gene expression. This mechanism can influence many processes in the cell 
including differentiation, lipid metabolism and the unfolded protein response (Brown et al., 2000). 
RIP has been shown to occur in animals and also in bacterial cells, using proteases that are 
evolutionary related to the ones used in animals (DeBose-Boyd et al., 1999; Haze et al., 1999; 
Katayama et al., 1999; Mumm et al., 2000; Niwa et al., 1999; Ray et al., 1999).
Periplasm Aggregation
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Figure (1.3) APP processing by a-, 0- and y-secretases.
Cleavage by a-secretase (PC7, TACE or ADAM-10) produces aAPP and the C-terminal fragment, C83. Both TACE
and ADAM-10 can be activated by protein kinase C (PKC) which is regulated by the muscarinic acetylcholine (Ach) 
receptor. C83 is cleaved by y-secretase to produce p3. Cleavage o f APP by P-secretase (BACE) produces PAPP and 
C99. y-secretase cleaves C99 to release Ap, which is the major component of the amyloid plaques of AD.
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1.4 Presenilin-1 (PS-1) and Presenilin-2 (PS-2)
PS-1 and PS-2 (Figure 1.4) are composed of a hydrophilic amino-terminus followed by eight 
putative transmembrane domains. Most of these regions are connected by small hydrophilic loops, 
except one longer stretch of mostly hydrophilic residues between transmembrane 6 and 7, called 
the ‘large loop’ (Czech et al., 2000).
1.4.1 Conservation among species
The PS proteins are 467 (PS-1) and 448(PS-2) amino-acids long. There is strong sequence 
homology between PS-1 and PS-2, and between homologues in different species (Rogaev et al., 
1995). Presenilins are present in many species such as humans, C. elegans (Levitan and Greenwald, 
1995) and D. melanogaster (Boulianne et al., 1997; Hong and Koo, 1997). They are also present in 
plants (Arabidopsis thaliana, NCBI sequence ID: gi 3063457), but seem to be restricted to 
multicellular organisms. The amino acid sequences in the hydrophobic regions are almost identical 
in PS-1 and PS-2, and highly conserved between species. Strong sequence homology was shown 
close to the carboxy-terminus region, which suggested an important role for this terminus in 
maintaining the structure and function of the protein. In contrast, the amino-terminus is poorly 
conserved (Czech et al., 2000).
1.4.2 Expression and post-translational modifications of the presenilins
The PS-1 and PS-2 genes are encoded by 12 exons giving rise to two major mRNA transcripts (7 
and 2.7 kb for PS-1, 2.3 and 2.6 kb for PS-2) (Rogaev et al., 1995; Sherrington et al., 1995), which 
undergo alternative splicing (Czech et al., 2000). Presenilin transcripts were detected in the brain 
and most peripheral tissue (Rogaev et al., 1995; Sherringdon et al., 1995). Both PS-1 and PS-2 co- 
localise in a large number of neuronal cell bodies, and PS-1 is also present in the processes of 
neurons (Blanchard et al., 1997).
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At the subcellular level, presenilins co-localise in the endoplasmic reticulum (ER) and Golgi 
apparatus (Cook et al., 1996; Culvenor et al., 1997; Kovacs et al., 1996; Takashima et al., 1996). 
They can be detected in synaptic terminals (Lah et al., 1997) and in somatic ER-Golgi intermediate 
compartment structures (Czech et al., 2000). They were also shown to be present on the inner 
nuclear envelope, the associated kinetochores and centrosomes which suggests a role in 
chromosomal segregation (Li et al., 1997). Finally, presenilins were found in the plasma membrane 
where they could be involved in cell-cell interaction (Dewji and Singer, 1997).
Presenilins are neither glycosylated nor modified by sulphation, acylation or the addition of 
glycosaminoglycans (De Strooper et al., 1997), but they are phosphorylated on serine residues 
(Seeger et al., 1997; Walter et al., 1997). The most important posttranslational modification of 
presenilins is proteolytic cleavage (Podlisny et al., 1997; Thinakaran et al., 1996). PS-1 is cleaved 
into a 27-28 kDa amino terminal and an 18-20kDa carboxy-terminal fragment, PS-2 into two 
polypeptides of 34 kDa and 20 kDa respectively. The presenilin cleavage products remain closely 
associated in a large non-covalent protein complex of 100-150 kDa (Capell et al., 1998). The 
cleavage of PS-1 occurs at amino acid position 298 encoded by exon 9 (Podlisny et al., 1997), a 
region where several PS mutations are clustered. Due to a splicing error, the PS-lAexon9 mutation 
results in the deletion of the domain encoded by exon 9 (Perez-Tur et al., 1995) and therefore 
PSlAexon9 accumulates as an uncleaved protein (Thinakaran et al., 1996). Since proteolytic 
processing is highly regulated, this mutation was expected to be responsible for the protein’s 
pathological activity (Steiner et al., 1999). However, it was demonstrated that the pathological 
function of PSlAexon9 as well as its reduced biological activity is independent of its lack to 
undergo proteolytic processing, but rather due to a point mutation (S290) that is the result of the 
abnormal exon 8/10 splice junction (Steiner et al., 1999).
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The presenilins are also processed by the proteases of the Caspase superfamily. Caspases are a 
conserved family of cytoplasmic cysteinyl aspartate-specific proteases, which are crucial for the 
physiological pathway to cell death, apoptosis(Cohen, 1997; Porter et al., 1997). According to 
amino acid sequence homology, caspases can be divided into 3 sub-families (Humke et al., 1998; 
Porter et al., 1997; Van de Craen et al., 1998; Van de Craen et al., 1997). During induced apoptosis, 
PS-1 and -2 are cleaved by a protease of the caspase-3 family (Loetscher et al., 1997), and FAD 
mutations do not seem to alter the sensitivity of PS-1 to caspase mediated cleavage (Van de Craen 
et al., 1999).
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Figure (1.4) Schematic representation of the most established structure of wild type PS-1 and
PS-lAexon9
(A) PSlwt, including the “large loop” which is the known site for proteolytic cleavage of the protein. (B) PSlAexon9
produced as a result of a splicing error of the mRNA. The mutation deletes exon 9 and results in lack of proteolytic 
processing and accumulation of the full-length protein.
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1.4.3 Functions of the presenilins
1.4.3.1 Presenilins and Notch processing
There was a considerable amount of data indicating that presenilins are involved in the Notch 
signalling pathway and that the processing of Notch resembles that of APP. During the passage of 
Notch through the Golgi system, it is processed by a furin-mediated cleavage. The resulting two 
fragments remain in the same protein complex and localise in the cellular membrane to form the 
functional receptor. The binding of the ligand to the receptor stimulates the cleavage of one of the 
subunits at a specific extracellular site close to the membrane. Subsequently, intra-membranous 
cleavage by PS-1 releases an intracellular fragment (Kopan and Goate, 2000) that travels to the 
nucleus and forms an active transcriptional complex, which activates transcription of Notch target 
genes (Artavanis-Tsakonas et al., 1999; Greenwald, 1998; Kimble and Simpson, 1997)
Recently, it was shown that presenilins in humans exist in a complex with the protein Nicastrin (Yu 
et al., 2000). The C. elegans orthologue of Nicastrin (Aph-2) is involved in Notch signaling during 
early embryogenesis although its exact function is unknown (Goutte et al., 2000). Goutte and co­
workers (2002) have also identified a protein called Aph-1 that is involved in Notch signaling in C. 
elegans. Mutations in the aph-1 gene cause the embryonic Aph phenotype which indicates 
defective Notch signaling. As a result of all these recent findings, it was thought that presenilins are 
part of a larger y-secretase complex which also includes Nicastrin, Aph-1 and possibly Notch 
(Goutte, 2002).
1.3.4.2 Other interaction partners of the presenilins
Presenilins have been found to interact with a variety of other proteins. A neuronal calcium-binding 
protein, Calsenilin (Buxbaum et al., 1998a) was found to interact with both PS-1 and PS-2, by 
using the yeast two-hybrid system. The brain G-protein Go was shown to interact with the carboxy-
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terminus of PS-1 which hinted towards a role of PS-1 as regulator of G-protein activation (Smine et 
al., 1998). Several proteins have been shown to interact with the ‘large loop’ of the presenilins 
including the cytoskeletal protein filamin and a filamin homologue (Zhang et al., 1998), p-calpain 
(Shinozaki et al., 1998) and rab ll a small GTPase belonging to the p21 ras related superfamily, 
which indicates that presenilins might be involved in vesicular routing (Dumanchin et al., 1999). 
Presenilins were also shown to bind to members of the catenin protein family (Levesque et al., 
1999; Murayama et al., 1998; Tesco et al., 1998; Zhou et al., 1997). The catenins form a gene 
family related to the Drosophila Armadillo gene and are characterised by a series of imperfect 
repeats of an amino acid motif (Peifer et al., 1994) These repeats in P- and A-catenin interact with 
the large loop of PS-1 (Levesque et al., 1999; Murayama et al., 1998). Catenins interact with 
cadherin adhesion molecules and they are thought to be essential for the wingless/wnt signaling 
cascade which directs many vital developmental decisions in Drosophila and vertebrates (Czech et 
al., 2 0 0 0 ).
1,5 The y-secretase complex
y-Secretase has eluded identification for many years though evidence suggested that presenilin (PS) 
is the active site of the protease (Wolfe and Selkoe, 2002). Presenilin is cleaved into N- and C- 
terminal fragments (NTF and CTF) that remain associated, and these heterodimers seem to be the 
biologically active form of the protein (Thinakaran et al., 1996). However, it appears that PS does 
not act alone, as the levels of PS heterodimers are tightly regulated by other limiting factors 
(Thinakaran et al., 1997), and overexpression of PS does not increase y-secretase activity and 
produce more product. It seems that PS carries out secretase function by forming a highly stable 
protein complex of high relative molecular mass with a number of cofactor proteins (Ratovitski et 
al., 1997; Takasugi et al., 2002). Other components of the y-secretase complex are now thought to 
be nicastrin (NicA), Pen-2 and Aph-1 (figure 1.5).
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1.5.1 Nicastrin (NicA)
Nicastrin (NicA), a type I transmembrane glycoprotein, was discovered via its association with 
presenilin (Yu et al., 2000) and it is thought to be one of the putative limiting factors for y-secretase 
activity. Deletion of NicA in C. elegans and D. melanogaster results in a phenotype similar to the 
deletion of presenilin (Chung and Struhl, 2001; Hu et al., 2002; Levitan et al., 2001; Lopez-Schier 
and St Johnston, 2002; Yu et al., 2000), and recent evidence has shown that NicA maturation 
depends on the presence of presenilin (Edbauer et al., 2002; Kimberly et al., 2002; Leem et al., 
2002; Tomita et al., 2002) and is directly associated with y-secretase (Esler et al., 2002; Kimberly 
et al., 2002). Nevertheless, over-expression of both PS and NicA was found to be insufficient to 
generate more y-secretase activity (Kimberley et al., 2002), which suggested that there were other 
limiting factors.
1.5.2 Pen-2 and Aph-1
Genetic screens designed to modify a PS-deficient phenotype in C. elegans have uncovered two 
novel genes, aph-1 (Goutte et al., 2002) and pen-2 (Francis et al., 2002). Aph-1 is a multi­
transmembrane protein encoded by a gene whose deletion leads to hypoplasia of the anterior 
pharynx in C. elegans and it was found to be a Notch pathway member possibly involved in PS 
function (Goutte et al., 2002) ; aph-1 was also identified as one of the PS enhancer genes (pen-1) 
together with pen-2 which codes for a double membrane spanning protein (Francis et al., 2002). 
Genetic analyses demonstrated that these proteins are needed for PS endoproteolysis and y- 
secretase activity (Francis et al., 2002), but their biochemical role remained unknown. Kimberley 
and co-workers (Kimberly et al., 2003) have shown that Aph-1 and Pen-2 directly associate with 
PS and NicA in the active protein complex. Co-expression of all four proteins leads to marked 
increases in PS heterodimers, full glycosylation of NicA, and enhanced y-secretase activity. These
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findings suggest that the four membrane proteins comprise the limiting components of y-secretase 
and co-assemble to form the active enzyme in mammalian cells.
Takasugi and co-workers (Takasugi et al., 2003) have shown that D. melanogaster Aph-1 increases 
the stability of Drosophila PS holoprotein in the complex. Depletion of Pen-2 by RNA interference 
(RNAi) prevents endoproteolysis of PS and promotes stabilisation of the holoprotein in both 
Drosophila and mammalian cells, including primary neurons. Co-expression of Drosophila Pen-2 
with Aph-1 and NicA increases the formation of PS fragments as well as y-secretase activity. 
Therefore, Aph-1 stabilises PS holoprotein in the complex, whereas Pen-2 is required for PS 
endoproteolysis and conferring y-secretase activity to the complex. So, these studies seem to 
provide strong evidence that y-secretase activity requires the formation of a complex between PS, 
NicA, Aph-1 and Pen-2, but it was unclear if the four components are sufficient for y-secretase 
activity. In higher eukaryotic cells, which all contain y-secretase activity this is impossible to prove 
as these cells may contain additional so-far unknown y-secretase components. Therefore co­
expression of the four known y-secretase complex components in such cells will not reveal the 
minimal composition of the biologically active y-secretase.
To define the minimal set of components required for y-secretase activity, Edbauer and co-workers 
(Edbauer et al., 2003) co-expressed PS, NicA, Aph-1 and Pen-2 in the yeast S. cerevisiae. No 
homologues have been identified in yeast and no endogenous y-secretase activity was detected. 
Although it is not possible to formally rule out the possibility that yeast may contain endogenous 
proteins required for this activity, it is considered improbable, given the complete absence of 
orthologous y-secretase complex components from the yeast genome. Therefore yeast may not 
contain other y-secretase binding proteins or cofactors of similar functional importance as PS,
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NicA, Aph-1 and Pen-2. Edbauer and co-workers also found that the biological activity of y- 
secretase is reconstituted by the co-expression of those four membrane proteins.
Membrane
Cytoplasm
Presenilin 1
APP/C99
Cytoplasm
Pen 2 Aph-1 Nicastrin
Figure (1.5) A diagramatic representation of the membrane proteins thought to form part of 
the y-secretase complex, in addition to the substrate for the protease, C99.
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1.6 Topological studies usine Alkaline Phosphatase ( pho-A) fusions
A fundamental element of the structure of a membrane protein and therefore its function is its 
transmembrane topology i.e. the location of segments of the polypeptide chain within the 
membrane, in the cytoplasm or in the periplasm. Work in this project utilises an E. coli system for 
the analysis of human membrane proteins. Therefore, it was important to ensure correct insertion of 
the recombinant proteins into the bacterial cytoplasmic membrane, so that they can perform their 
intended function.
In theory, any region of about 20 hydrophobic amino acid residues corresponds to a 
transmembrane helix (Kyte and Doolittle, 1982) and therefore, the amino acid sequence of any 
protein can be used to predict its transmembrane domains. The topology of integral cytoplasmic 
membrane proteins in E. coli can be studied in vivo by a genetic approach developed in the late 
eighties, which involves generating hybrids of the target membrane protein to PhoA (Manoil and 
Beckwith, 1986; Manoil et al., 1990). In wild-type strains, PhoA is only active after being exported 
to the periplasm where its disulphide bonds can be formed as a result of the oxidising environment 
in the periplasm (Derman and Beckwith, 1991).
Periplasmic domains of integral membrane proteins can be fused to signal sequenceless PhoA, 
subsequently the activity of PhoA can be investigated (Manoil and Beckwith, 1986). When PhoA is 
fused to a cytoplasmic domain it is enzymatically inactive. Therefore, the activity of phoA fusions 
is used to predict the cellular localisation of the fused membrane protein domain (Boyd et al., 
1993b; Ehrmann et al., 1990) (Figure 1.6). In this work, we constructed Pen-2-PhoA and Aph-1- 
PhoA fusions, to help us identify the topology of human Pen-2 and Aph-1 in the bacterial 
membrane. Each individual fusion joint was placed at the C-terminus of each hydrophilic region of 
the membrane protein. Boyd and co-workers introduced this experimental strategy in order to
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minimise the disruption of topological signals (Boyd et al., 1993a). Additionally, we describe 
previous work performed to analyse the topological structure of human PS-1 in E. coli.
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Figure (1.6) A genetic system to study the topology of membrane proteins using pho-A
fusions.
Bacterial alkaline phosphatase (PhoA) is only active when it is translocated to the periplasm where its disulphide bonds 
can form as a result of the oxidising environment. (A) The activity of PhoA can be used to predict the position of the 
fusion joint and therefore the position of the transmembrane domains of the investigated protein. (B) The activity of 
PhoA can be detected on indicator plates containing Arabinose and the PhoA substrate. When PhoA is in the Periplasm 
and therefore active, a dark blue colour change is seen. Picture in (B) is taken from: beck2.med.harvard.edu/ 
Pictures/Dana_Boyd_gram.jpg
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1.7 Use o f two-hybrid systems for the detection of protein-protein interactions
1.7.1 General two-hybrid systems
Protein-protein interactions are essential for biological processes, and their detection is required for 
understanding molecular mechanisms. Two hybrid systems have been used as a general tool for 
monitoring protein-protein interactions, and yeast two-hybrid systems have been developed and 
used for this purpose successfully.
In the yeast two-hybrid systems, two fusion proteins are expressed in cells. One is known as the 
bait and it contains a site-specific DNA binding domain (DBD) fused to a protein of interest. This 
fusion protein binds to an operator adjacent to a promoter. The second is called the prey and it 
contains the transcriptional activation domain fused to a second protein of interest. If the fused 
proteins interact, the bait hybrid bound to the operator will recruit the prey hybrid from solution 
and position it close to the promoter. This results in the activation of the promoter by the activation 
domain of the prey hybrid. The interaction between the hybrids can be made to generate an easily 
detectable phenotype by placing a suitable reporter gene under the control of the prey-dependent 
promoter (Hu et al., 2000).
Designing a two-hybrid method that utilises E. coli instead of yeast is valuable for many reasons. 
One of the advantages of using an E. coli two-hybrid system is the speed with which large numbers 
of interactions can be tested. E. coli grows much faster than yeast and can be transformed with 
higher efficiency, allowing better coverage in library-based screens. In addition, since the cloning 
steps in yeast often involve passing libraries through E. coli hosts, using E. coli removes a step 
from each cycle in a screening program. Furthermore, eukaryotic regulatory proteins such as cell 
cycle components may be toxic in yeast by interfering with the functions of their yeast homologues. 
This problem is unlikely to occur in E. coli although heterologous proteins may be toxic for other
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reasons that are unrelated to function. The smaller genome complexity of E. coli and greater 
evolutionary distance from higher eukaryotes mean that E. coli two-hybrid systems should not 
generate as many false positives and negatives due to interactions between endogenous proteins 
and eukaryotic bait and prey. Finally, E. coli may be a better host for drug screening because its 
cell envelope seems to be more permeable to small molecules than the cell wall of yeast (Hu et al., 
2000).
1.7.2 E. coli two-hybrid systems
RNA polymerase (RNAP) in E. coli consists of an enzymatic core composed of subunits a , p and 
P’ in the stoichiometry o^PP’, and one of several ct factors that is necessary for the enzyme to be 
able to recognise specific promoters (Helmann and Chamberlin, 1988). It has been shown that any 
protein-protein contact can activate transcription in E. coli provided one of the interacting fusion 
proteins is bound to the DNA via a DBD and the other is bound to an RNAP subunit (Dove et al., 
1997).
The generality of this system was tested using two eukaryotic protein domains known to interact 
specifically (Hu et al., 2000). The dimerisation domain of the yeast transcription factor Gal4 and a 
part of the yeast Gall l p protein. Gall 1 is a component of the RNAP II holoenzyme and Gall l p is a 
mutant form that interacts with the dimerisation domain of Gal4. Gal4 was fused to full-length 
lambda repressor protein (A,cl) at its C-terminus, and Gall l p was fused to the N-terminal domain of 
the a-subunit of RNAP. The Xcl-Gal4 fusion protein was found to stimulate transcription from the 
test promoter, but only in the presence of the a- Gall l p fusion (Hu et al., 2000) (Figure 1.7).
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Figure (1.7) Transcription by E. coli RNA polymerase (RNAP).
A promoter consisting of a -10 and a -35 element is shown together with the subunit composition of RNAP
holoenzyme. The a-Gal 11p fusion protein interacts with the Gal4 dimerisation domain of the Xcl-Gal4 fusion protein. 
The diagram shows the test promoter placOR2-62, which bears the X operator Or2 centred 62 bp upstream of the 
transcriptional start site of the lac promoter. Taken from: Dove and Hochschild (1998).
An additional protein, omega (co), has been called a subunit of RNAP on the basis of its co­
purification with RNAP core and holoenzyme (Burgess, 1969). The function of co is unknown and 
it was not found to be required for transcription either in vitro (Heil and Zillig, 1970) or in vivo 
(Gentry et al., 1991; Gentry and Burgess, 1989), unlike other RNAP subunits. Cells deleted for the 
gene encoding co (rpoZ) have no observable mutant phenotypes (Gentry and Burgess 1989; Gentry 
et al., 1991). Dove and Hochschild (Dove and Hochschild, 1998) showed that co is another one of 
the RNAP subunits that could be used to generate a two-hybrid system. They fused the Gal 11p 
fragment to co and demonstrated that the Xcl-Gal4 fusion protein activated transcription in cells 
containing the co-Gal 11p fusion protein.
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1.8 Aims of the project
AD remains to be the most widespread form of progressive dementia in the world and it is now 
becoming a social and economic problem, especially in industrial countries as the average age of 
the population is increasing. The y-secretase complex cleaves the substrate C99, to produce Ap 
peptides, which aggregate to form the plaques found to be deposited in the brains of AD sufferers. 
Identifying the proteins that constitute the y-secretase complex and determining how the different 
components interact with each other to bring about y-secretase activity, would generate possible 
drug targets for the treatment of AD. A number of laboratories are working on the y-secretase 
complex and have shown that the y-secretase complex is comprised of Pen-2, Aph-1, NicA and PS- 
1 (Edbauer, et al., 2003). However, in eukaryotic cells, other so-far unknown y-secretase 
components may exist. Therefore, bacteria was thought to be a more suitable organism for the 
reconstitution of y-secretase activity. In addition to the lack of endogenous proteins, bacteria have a 
very simple genome, are easy to cultivate and there are numerous bacterial expression vectors 
available, which are suitable for recombinant protein expression.
The first aim of the project was to produce the y-secretase complex components in E. coli by 
cloning the genes encoding them into suitable vectors and subsequently expressing them. Once a 
good expression level was reached, the second aim was to verify that the components had the 
correct topology in the bacterial membrane. Finally, the E. coli two hybrid system was used to 
analyse interactions between the different components, and to screen for interaction partners of PS- 
1 which was thought to be the active site of the complex, and the PS-1 gain of function mutant PS- 
1 Aexon9 which was shown to be involved in FAD.
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2. MATERIALS AND METHODS
2.1 Laboratory chemicals. enzymes and their suppliers
Acrylamide
Ampicillin
Arabinose
BCIP
Big Dye terminator V3.0 kit
Chloramphenicol
DMSO
DNA standard (y-DNA BstEII 
Digested, 1 kb and lOObp) 
IPTG 
NBT
Ni NT A superflow 
Pfu polymerase 
Plasmid preparation kit 
Protein standards 
Oligonucleotides 
Qiaquick kit 
Restriction enzymes 
Tetracycline 
T4 ligase 
Vent polymerase
ICN (Basingstoke, Hampshire, UK) 
AppliChem (Darmstadt, Germany)
Sigma (Poole, Dorset, England)
Sigma (Poole, Dorset, England)
ABI, Applied Biosystems (Warrington, UK) 
Sigma (Poole, Dorset, England)
AppliChem (Darmstadt, Germany)
New England Biolabs (Beverly, MA, USA)
Promega (Madison, WI, USA)
AppliChem (Darmstadt, Germany) 
QIAGEN (Crawley, West Sussex, UK) 
Stratagene (Cambridge, UK)
QIAGEN (Crawley, West Sussex, UK) 
Biorad (Hertfordshire, UK)
QIAGEN (Crawley, West Sussex, UK) 
QIAGEN (Crawley, West Sussex, UK)
New England Biolabs (Beverly, MA, USA) 
Fluka (Buchs, Switzerland)
Promega (Madison, WI, USA)
New England Biolabs (Beverly, MA, USA)
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Further chemicals not listed above were purchased from Merck (Dorset, England), Sigma (Poole, 
Dorset, England), Boehringer Mannheim (Lewes, East Sussex, UK), ICN (Basingstoke, Hampshire, 
UK), Peqlab (Ehrlangen, Germany) or Roche (Lewes, East Sussex, UK).
2.2 M icrobiological methods
2.2.1 E. coli Strains
CB4 MC4100 F’ OR2-62SD6/a Christian Behrends 1
lacZ with XL1 MRF‘Kan Diplom Thesis (2002)
DHB4 AmalF3 AphoA (PvuII) 
phoR recAr.cat is 
araD\39 A(ara-leu)1691 
AlacXIA galE galK thi 
rpsL V lac f t  pro
Ehrmann
Collection
Laboratory
KS272 KS272\F-raDl3 9A(ara- 
leu) 7697AlacYZI74 galE 
galK rpsL
Ehrmann
Collection
Laboratory
KU98 degP::kan treA r.spec Ehrmann
Collection
Laboratory
MC1000 F-araDl 3 9A (ara-leu) 
7697AlacYZ174 galE galK 
rpsL
Ehrmann
Collection
Laboratory
MC4100 araD139 deoCl flbB530l 
ptsF25 rbsR relAl rpsL 
150 A(argF-lac) U169
Ehrmann
Collection
Laboratory
XLl-BIue MRF’ Kan A(mcrA) 183 A {mcrCB- 
hsdSMR-mrr) 173 endA 1 
supE44 thi-1 recAl 
gyrA96 relAl lac [F* 
proAB lacfiZAMTnJ 
(Kan')]
Stratagene
XLl-Blue MRF’ 
Reporter strain
A (mcrA) 183 A{mcrCB- 
hsdSMR-mrr) 173 endA 1 
supE44 thi-1 recAl 
gyrA96 relAl [F’ 
bla lacZ (Kan')]
Stratagene
Table (2.1) Description of used E.coli strains
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2.2.2 Media
2.2.2.1 Sterilisation
Media, solutions and glassware were sterilised by autoclaving (20 min. 121 °C, 1 bar). Solutions 
sensitive to heat such as antibiotics or sugar solutions were filter sterilised by passing through a 
Millipore filter (diameter 0.2 pm).
2.2.2.2 Liquid and solid media (per 1 1 distilled water)
LB (Luna Bertani) 10 g Bacto Tryptone
5 g Bacto Yeast Extract
7.5 g NaCl
(5 g Bacto Agar for Top Agar)
NZA (NZ Amine A) lO gN ZA
5 g Bacto Yeast Extract 
5 g NaCl
(17 g Bacto Agar for plates)
SOB 20 g Bacto Tryptone
10 g Bacto Yeast Extract 
5 g NaCl
2.5 g K2 HP0 4
MacConkev plates 50 g MacConkey lactose agar
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M9 IPX 76.54 g Na2 HP04  x 2H20
30 g KH2P 0 2 
5 g NaCl 
10 g NH4 CI
For minimal agar plates, 17 g extra pure agar was used. Subsequently, 100 ml M9 10X were added 
to the agar, followed by MgS04  (1 mM F.C.), CaCl2  (0.1 mM F.C.), 1 ml 20% Casamino acids, X- 
Gal (10 fig/ml F.C.) and the desired antibiotics.
2.2.23 Media supplements
Amp 2 0 0  mg/ml in 
sterile H2 Omq
2 0 0  pg/ml 4°C- 8 °C
Arabinose 1 0 % in distilled 
H20
0 .1 % -20°C
A-tetracycline 1 mg/ml in EtOH 1 0 0  ng/ml -20°C
BCIP/XP 30 mg/ml in DMF 0.03 mg/ml 4°C- 8 °C
CaCl2 100 mM in 
distilled H20
0.1 mM Room temperature
Casamino acids 2 0 % (w/v) in 
distilled H20
0 .0 2 % Room temperature
Cm 30 mg/ml in 100% 
EtOH.
30 pg/ml 4°C- 8 °C
IPTG 1 M in distilled 
H20
1 0 0  pg/ml -20°C
Kan 1 0 0  mg/ml in 
sterile H2Omq
1 0 0  pg/ml 4°C- 8 °C
M gS04 1 M in distilled
h 2o
1 mM Room temperature
Tet 5-20 mg/ml in 
100% EtOH
5-20 pg/ml -20°C
X-Gal 1 0  mg/ml in 1 0 0 % 
DMF
10-40 pg/ml -20°C
Table (2.2) Media supplements
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2.2.3 Growth conditions and storage of E.coli
Liquid cultures (5 ml) were grown in 20 ml glass reaction tubes, in a culture roller drum (about 50 
rpm), at 37°C or 28°C. Liquid cultures over 5 ml were grown in Erlenmeyer flasks, with a volume 
about 4-5 times bigger than the culture volume, at 37°C or 28°C in incubator chests, shaking at 220 
rpm. Cultures on agar plates were grown at 37°C or 28°C for 10 to 15 hours. DMSO cultures were 
prepared for storage of bacterial strains at -80°C, by mixing 1.7 ml of an overnight culture grown in 
NZA medium with 126 pi DMSO (F.C. 7% DMSO) and quickly freezing them. Stab cultures were 
used for storage of bacterial strains at room temperature. 1 ml Top-Agar without antibiotics is 
inoculated with a single colony from an agar plate and incubated for 10 to 15 hours at 37°C or 
28°C.
2.2.4 Plate assay system for two-hybrid interactions
A simple plate assay system was developed for the detection of protein-protein interactions. The 
system involves the use of indicator plates such as MacConkey lactose agar plates and NZA or 
minimal plates containing 10 pg/ml X-Gal to detect positive two-hybrid interactions. If bait and 
trait interact, transcription of lacZ is elevated up to 50 fold over background and thus a colour 
change is seen on the indicator plates. On MacConkey plates, background is seen as white/pale red, 
and a positive interaction is red/dark red. On X-Gal plates, background is white/pale blue and a 
positive interaction is blue/dark blue.
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2.3 M olecular biological methods
2.3.1 Plasmids
pCBl pslw t via Notl/BgUI Cm Christian Behrends, 
Diplom Thesis 
(2 0 0 2 )
pCB13 pslAexon9 via Notl/BgUI Cm Christian Behrends, 
Diplom Thesis 
(2 0 0 2 )
pCB6 pslw t and C99co Cm Christian Behrends, 
Diplom Thesis 
(2 0 0 2 )
pACA.cI3.2 Lambda Repressor Cm Hochschild et al., 
1998
pACLGF2 Lambda Repressor-Gal4 Cm Hochschild et a l , 
1998
pBRstar a a  subunit of RNA 
polymerase
Tet Hochschild et al., 
1998
PBRomega
GalllP
co-Gall IP Amp Hochschild et al., 
1998
pBRstar
aG alllP
a-Gall IP Tet Hochschild et al., 
1998
pTRG XR- 
cDNA
cDNA library Tet Stratagene
PRW50/417 Reporter lacZ gene Tet Hochschild
Laboratory
Collection
pGDRll pQE31 derivative lacft Amp Ehrmann Laboratory 
Collection
pCS19 pQE-60 derivative lacf~ Amp Christoph Spiess, 
PhD Thesis (1999)
pSAl pen2 in pGDRl 1 via 
KpnI/BamHI
Amp This Work
pSA2 aphl splice variant in 
pGDRl 1 via KpnI/Hindlll
Amp This Work
pSA3 pen2 fragment 1 in pEDIE3 Amp This Work
pSA4 pen2 fragment 2 in pEDIE3 Amp This Work
pSA5 aphl fragment 1 in pEDIE3 Amp This Work
pSA6 aphl fragment 2 in pEDIE3 Amp This Work
pSA7 aphl fragment 3 in pEDIE3 Amp This Work
pSA8 aphl fragment 4 in pEDIE3 Amp This Work
pSA9 aphl fragment 5 in pEDIE3 Amp This Work
pSAlO aphl fragment 6  in pEDIE3 Amp This Work
pSAll pen2 in pCS 19 via Ncol and 
HindHI
Amp This Work
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pSA12 aphl in pGDRll via 
Kpnl/HindM
Amp This Work
PSA13 aphl amplified from pSA2 
and cloned into pSAl via 
Sail and Hindlll
Amp This Work
pSA14 aphl amplified from pSA12 
and cloned into pSAl via 
Sail and Hindlll
Amp This work
pSA16 pen-2 amplified from 
pSA ll and cloned into 
pSAl4 via Sail and Xhol
Amp This work
pSA18 tf/?/z-/amplified from pSA12 
and cloned into pSA ll via 
Hindlll and Nhel
Amp This work
pSA19 aph-1 simplified from 
pcDNA (zeo) Aphla251 
and cloned into pBRco via 
Sail and Not!
Amp This work
pSA20 aph-1 amplified from 
pcDNA (zeo) Aphla251 
and cloned into pCBl via 
Bglll and Not I
Cm This work
pSA21 nicA amplified from 
pMH42 and cloned into 
pBRco via Ndel and Notl
Amp This work
pEDIE3 Cloning vector for phoA 
fusions
Amp Ehrmann Laboratory 
Collection
pSG33 p s l  wt and c99 Cm Sandra Grau, PhD 
Thesis (2004)
pSG34 pslAexon9 Cm Sandra Grau, PhD 
Thesis (2004)
pBRco co-subunit of RNAP Amp Ehrmann Laboratory 
Collection
pSG6 Assc99 via Ncol and Bglll Amp Sandra Grau, PhD 
Thesis (2004)
pMHl p sl via Ncol and Bglll Amp Mona Hamasch, 
PhD Thesis (2003)
pMHll pslAexon9 via Ncol and 
Bglll
Amp Mona Hamasch, 
PhD Thesis (2003)
pMH13 pslAexon9 via BamHl and 
Hindlll
Amp Mona Hamasch, 
PhD Thesis (2003)
pMH42 nicA via Kpnl and Sail Amp Mona Hamasch, 
PhD Thesis (2003)
pSG36 nicA via BamHI and Ncol Kan Sandra Grau, 
Ehrmann Laboratory
pCDNA (zeo) 
Aphla251
Full length Aphl Amp Haass Laboratory, 
Munich
Table (2.3) List of plasmids used
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2.3.2 Oligonucleotides
Coding 
strand of 
cDNA library
CGT C AGCCT GAAGT GAAAG AAG cDNA library £.coli 
two-hybrid screen
pen2-
5 '{BamHD
CGGGATCCGAACCTGGAGCGAGTGTC
CAATGAGGAG
pSAl cloning
pen2-3’ 
(Kpnl)
GGGGT ACCtC AGGGGGTGCC AGGGGT A 
TGGTGAAGG
pSAl cloning
AphI/Ap/f//p
GDR11
GGGGT ACCT GCTGCGGT GTTTTT CGGC 
TGCACTTTCGTCG
pSA2 and pSA12 
cloning
Aphl IH indlll 
/pGDRll
GGTGAAGCTTTCAGTCCAGGTAGTCAG 
TCCTT AC AC AAG AGC
pSA2 and pSA12 
cloning
pen2-5’
cNcol)
CTTCCCATGGCAAACCTGGAGCGAGTG
TCCAATGAGGAG
pSAl 1 cloning
pen2-3’
{Hindlll)
GGTGAAGCTTTCAGGGGGTGCCCAGG
GGTATGGTGAAGG
pSAl 1 cloning
SDpGDRll/5
all
GTGGGTCGACAAAGAGGAGAAATTAA
CTATGAGAGG
pSA13 and pSA14 
cloning
Aphl IH indlll
/pGDRll
nones
GGTGAAGCTTTCAGTCCAGGTAGTCAG 
TCCTTAC AC AAG AGC
pSA13 and pSA14 
cloning
universal-fw- 
Xm al (Pen-2)
CCCCCCGGGAACCTGGAGCGAGTGTCC
AATGAGG
pSA3 and pSA4 
cloning
60-XbaI-rev GCTCT AGAGAGCGCC AGAC AT AGCCTT 
TGATTTGG
pSA3 and pSA4 
cloning
\01-XbaI-rev GcTCTAGAGGGGTGCCCAGGGGTATGG
TGAAGG
pSA3 and pSA4 
cloning
universal-fw- 
Xm al (Aph-1)
CCCCCCGGGGCT GCGGT GTTTTT CGGC 
TGCACTTTCG
pSA5-pSA10
cloning
30-XbaI-re\ GCTCTAGAAGCGGGTCCCCAGCCACA
GTGATCAAG
pSA5-pSA10
cloning
116-XbaI-rex GCTCT AGAT GGCGG AT GGAGAT GGGT 
GATCTTCCG
pSA5-pSA10
cloning
154-XbaI-rex GCTCT AG AGGT G AGTCTCC AT GGATCC 
CAACCAC
pSA5-pSA10
cloning
\86-XbaI-rex GCTCTAGACGTCTCCTCTCACAGGCAT
CAAAGAAC
pSA5-pSA10
cloning
213-XbaI-rex GCTCT AG ACTGGCCT CAT ACC AGGGGT 
TCAGGAATG
pSA5-pSA10
cloning
251-XbaI-rex GCTCTAGATCCAGGTAGTCAGTCCTTA
CACAAGAGC
pSA5-pSA10
cloning
Pen2-3’(S<i//) GTGGGTCGACTCAGGGGGTGCCCAGG
GGTATGGTGAAGG
pSA16 cloning
(internal 
Xhol site)
GCATTTATCAGGGTTATTGTCTCATGA
GCGG
pSA16 cloning
SDAphl Hind GGTGAAGCTT G AGG AGAAATT AACT A pSA18 cloning
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m TGGGGGCTGCGGTGTTTTTCGGC
V N h e l CGTGCTAGCTCAGTCCAGGTAGTCAGT 
CCTT AC AC AAG AGC
pSA18 cloning
w-ApM/SdZ T GGGTCGACT C AGTCC AGGT AGTC AGT 
CCTT AC AC
pSA19 cloning
w -A p U /iM AGAGCGGCCGCTGCGGTGTTTTTCGGC
TGCACTTTCG
pSA19 cloning
cI-ApU JN etl AGAGCGGCCGCAGTGTTTTTCGGCTGC
ACTTTCGTCG
pSA20 cloning
cI-ApM/Jfctff TGAGATCTTCAGTCCAGGTAGTCAGTC
CTTACAC
pSA20 cloning
w-NkA/MfeT GGAATTCCATATGGAGGGCAAAAAAT
GAAAAAGACAGCTATCG
pSA21 cloning
w-NicA/Nbtf AGAGCGGCCGCGTATGACACAGCTCCT
GGCTCCCG
pSA21 cloning
Table (2.4) List of primers used
2.3.3 Preparation of double stranded plasmid DNA
The plasmid preparation kits from Qiagen were used for double-stranded DNA preparation. The 
Qiagen Mini/Maxi preparation kits were used for minipreparations from a culture volume of 5 ml 
and midipreparations from a culture volume of 1 0 0 - 2 0 0  ml.
2.3.4 Restriction digestion of double stranded plasmid DNA
Restriction digests were mainly used for genotypic checks of constructed plasmids and for cloning 
purposes. The enzymes were used in their recommended buffers to achieve an optimal result. A 
typical reaction was as follows:
X pi DNA (0.5-1 pg for plasmid checks and 8-15 pg for cloning)l 
1 / 1 0  pi restriction buffer lOx 
X pi restriction enzyme (5-10 u/pg DNA)
Made up to 20 pi with H2 OMQ for plasmid checks and 100 pi for cloning.
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Incubation time was 1-3 hours, or for enzymes with very low activity O/N at the recommended 
temperature. If possible, the enzyme was heat-inactivated by incubation for 10 minutes at 65°C or 
by adding 1 / 1 0  volume of agarose gel loading buffer.
2.3.5 Separation of DNA fragments on agarose gels
Plasmid DNA was separated on 0.7-1.7% (w/v) agarose gels in IX TAE buffer (40 mM Tris, 1 pM 
EDTA pH 8.0, 0.1% Acetic Acid) with a constant voltage of 100 V. The DNA was then stained in 
an ethidium bromide bath (1 pg/ml in TAE buffer) thereby the bands became visible in UV light. 
To identify the size of the DNA fragments they were compared to a number of base-pair standards 
(X-DNA BstE II digested, 100 bp ladder and 1 kb ladder, New England Biolabs).
2.3.6 Isolation of DNA fragments from agarose gels
After staining of the DNA fragment with ethidium bromide, it was cut out of the gel with a scalpel. 
Subsequently the fragment was purified and eluted using a QIAQuick Gel Extraction Kit from 
Qiagen in accordance with the manufacturer’s instructions.
2.3.7 Ligation of compatible ends of vector and insert
After extraction and elution of vector and insert fragments from the agrose gel, they were mixed in 
a 1:5 and 1:8 ratio (vector: insert) . 1 pi of T4 DNA Ligase (Promega) and 2 pi 1 Ox Ligase buffer 
were added to each assay and the volume was made up to 20 pi with sterile H2 OMQ. A sample with 
vector without insert served as a control for the ligation.
For ligation of sticky ends, ligation reactions were incubated in a beaker filled with water at room 
temperature for a few hours, and then overnight at 4°C in a closed styrofoam box. Subsequently, the
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DNA ligase was inactivated by incubation at 65°C for 10 minutes. 1 pi of the ligation reactions was 
transformed into competent cells by electroporation (described below section 2.3.8.2).
2.3.8 Transformation
2.3.8.1 TSS transformation
This method was used for low-yield transformations. All transformations were performed using this 
method and all incubations and growing steps were done at the appropriate temperature of 37°C or 
28°C, unless stated otherwise.
NZA or LB liquid media (5 ml), containing the appropriate antibiotics, were inoculated with a 
single E.coli colony and grown O/N. The O/N culture was diluted 1/50 in NZA and antibiotics, and 
grown to an optical density of about 0.5 at 600 nm (OD6 0 0  = 0.5). The culture at log phase was 
mixed with ice-cold 2x TSS (20% (w/v) PEG-6000, 10% (v/v) DMSO, 100 mM MgSC>4 . Dissolved 
in LB/NZA medium), and plasmid DNA (1-2 pi) was added to 100 pi TSS/culture mixture and 
incubated on ice for 20-30 minutes. Subsequently, 1 ml NZA was added and a phenotypic 
expression for 1 hour was performed at the appropriate temperature. The cells were pelleted and 
resuspended in approximately 200 pi medium and then plated on NZA agar plates with the 
appropriate antibiotics and incubated O/N.
2.3.8.2 Electrotransformation
This method was used for high yield transformations and was performed according to the BioRad 
Electroporation Application Guide (Catalogue number: 165-2100).
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Preparation of electro-competent cells
An overnight culture was diluted 1/100 in NZA (+/- antibiotics) and was grown at the appropriate 
temperature to an OD6 0 0  of 0.5-1.0. The culture was chilled on ice for 15-30 minutes and 
centrifuged for 10 minutes at 5000 rpm in a GSA rotor. The supernatant was discarded and the 
pellet was resuspended in 1 volume of ice-cold sterile H2 OMQ. The cells were then sedimented by 
centrifugation for 10 minutes at 5000 rpm in a GSA rotor and the pellet resuspended in 1/2 volume 
of ice-cold sterile H2 OMQ. A third centifugation step, analogous to the steps before, was performed 
and the sedimented cells were resuspended in 1/50 volume of 10% ice-cold sterile glycerol. After 
sedimenting the cells by centrifugation for 10 minutes at 5000 rpm, the pellets were resuspended in 
1/500 volume of 10 % ice-cold glycerol and aliquoted into 40 pi fractions. The aliquots were 
quickly frozen and stored at -80°C.
Electroporation
Competent cells were thawed on ice. Aliquots (1-3 pi) of the DNA were added to a 40 pi cell 
aliquot and transferred to a 0.2 cm electroporation cuvette. An electric pulse of 2.5 kV (setting EC2 
on the micropulser) was used and the cells were immediately transferred into 1 ml NZA medium 
and incubated at 37°C or 28°C for 1 hour in an incubator. The cells were pelleted and resuspended 
in approximately 200 pi medium and were plated on agar plates containing the required antibiotics.
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2.3.9 The Polymerase chain reaction (PCR)
PCR was used to amplify specific DNA fragments, for example for use in cloning. A typical 
reaction is shown below:
DNA (plasmid prep) 2 pi
DNA polymerase 3 u/pl
Polymerase buffer 10 pi 10X
ATP/GTP/CTP/TTP 2.5 mM each
DMSO 10 pi
BSA 1 pi 1 OX
Primers 2 pi each (0.5 pg/ml)
The reaction volume was made up to 100 pi with sterile H2 OMQ
The reaction was then placed in a Thermo-cycler (Biometra), and the protocol was adjusted to the 
melting temperature of the primers, the speed of the DNA polymerase used and the length of the 
DNA fragment to be amplified. A typical cycle is described below:
1 ) 94°C 3 min
2 ) 'O 0 n 30 seconds
3) 5°C below Tm of primer 1 min
4) 72°C 1 - 2  min per kb
5) 72°C 7 min
Steps 2-4 were repeated about 35 times. The reactions were analysed by agarose gel
electrophoresis.
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2.3.10 DNA sequencing of genes encoding PS-1 and PS-lAexon9 interacting partners
2.3.10.1 The Sequencing Reaction
Big Dye Terminator V3.0 ready 
reaction mix (ABI) 1 u 1
Better Buffer 5 nl
DNA (miniprep) 3 Hi
Primer (coding strand) 1 Hi
h 2o 7 Hi
Total 17 Hi
Table (2.5) Reagents used for the sequencing reaction
2.3.10.2 The Polymerase Chain Reaction (PCR) for Sequencing
This PCR was used to amplify DNA fragments for sequencing purposes. The reaction used is 
described below:
25 cycles
Step 1: Rapid ramp (l°C/sec) to 96°C for 10 sec 
Step 2: Rapid ramp (l°C/sec) to 50°C for 5 sec 
Step 3: Rapid ramp (l°C/sec) to 60°C for 4 min 
Step5: Hold at 4°C
2.3.10.3 Purifying Extension Products
To remove unincorporated dye-labelled terminators, the PCR products were precipitated in 60% 
isopropanol and rinsed afterwards with 75% isopropanol:
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85 pi 70% isopropanol was added to each sample (in a 0.5 ml tube; F.C. 60%), vortexed briefly and 
the samples were left at room temperature for 10 minutes to precipitate the extension products. The 
samples were then spun at maximum speed for 20-30 minutes, and the supernatant was removed. 
150 pi 75% isopropanol was added, the samples spun at maximum speed for 10 minutes and the 
supernatant removed. The pellet was then dried in air or gentle heat, and either analysed 
immediately or stored at room temperature.
2A  Biochem ical methods
2.4.1 Antibodies
Anti Penta His Mouse Qiagen (Crawley, West 
Sussex, UK). Catalogue 
number: 3466
Anti N-PS-1 Rabbit Santa Cruz Biotechnology, 
Inc; USA. Catalogue 
number: 5c-7860
Anti C99 Rabbit Zymed laboratories, USA. 
Catalogue number: 51- 
2700
Anti PhoA Mouse Caltag laboratories, 
Burlingame, Canada. 
Catalogue number: 
ME6200
Anti Ap Rabbit Santa Cruz Biotechnology, 
Inc; USA. Catalogue 
number: sc-9129
Anti Pen-2 Rabbit Christian Haass, Munich
Anti Aph-1 Rabbit Christian Haass, Munich
Anti NicA Rabbit Sigma-Aldrich, UK
Anti mouse secondary 
antibody, AP coupled
Rabbit Sigma-Aldrich, UK. 
Catalogue number: A-4312
Anti rabbit secondary 
antibody, AP coupled
Goat Sigma-Aldrich, UK. 
Catalogue number: A-8025
Table (2.6) List of antibodies used
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2.4.2 TCA (Trichloroacetic acid) precipitation of proteins
This method was occasionally performed to concentrate protein samples. Ice cold 20% TCA was 
added to the protein sample (7% F.C.). The mixture was vortexed and incubated on ice for 30 
minutes. The precipitated proteins were then sedimented by centrifugation in a cold table top 
centrifuge at 13,000 rpm for 10 minutes. The pellet was washed with 100% acetone and sedimented 
again as described. The protein pellet was then resuspended in sample buffer and analysed by SDS 
PAGE.
2.4.3 SDS PAGE
SDS PAGE is the electrophoretic separation of proteins in an SDS gel. Depending on the molecular 
weight of the investigated protein, different percentages of SDS gels were used (Table 2.7). The 
gels were prepared in a BioRad apparatus and 10-20 pi of samples were loaded carefully. The gels 
were run at 0.25A per gel for about an hour. Afterwards the gels were either blotted (Section 2.4.6, 
Materials and Methods), or stained with Coomassie Brilliant Blue from AppliChem, Germany 
(Section 2.4.4, Materials and Methods). Schaegger gels were used for the separation of proteins
with low molecular weights (Table 2.8).
Buffer A 
(1.5 M Tris-HCl 
buffer pH 8.8, 
0.4 % SDS)
2.5 ml 2.5 ml 2.5 ml 2.5 ml *
Buffer B 
(0.5 M Tris-HCl 
buffer pH 6.8, 
0.4% SDS)
* * * * 2  ml
Acrylamide 
stock (30%)
1.75
ml
2.5 ml 3 ml 3.75 ml 0.9 ml
H2 O 5.75
ml
5 ml 4.5 ml 3.75 ml 5.1 ml
TEMED 1 0  pi 1 0  pi 1 0  pi 25 pi 2 0  pi
APS (stock 1%) 25 pi 25 pi 25 pi 25 pi 40 pi
Table (2.7) Composition of SDS minigels
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Acrylamide 
(49.5% = 48 g / 
100 ml 
acrylamide; 3% = 
1.5 g / 100 ml 
bisacrylamide)
3.5 ml 1.5 ml 0.5 ml
Gel buffer (3 M 
Tris-HCl buffer 
pH 8.45; 0.3% 
SDS)
3.5 ml 2.5 ml 1.55 ml
H2 O * 3.5 ml 4.2 ml
32% glycerol 3.5 ml ♦ *
APS (10%) 32.5 pi 35 pi 25 pi
TEMED 1 0  pi 1 0  pi 1 0  pi
Table (2.8) Composition of Schaegger gels
2.4.4 R apid staining procedure with coom assie blue (W ong et al., 2000)
This is a modification of the staining procedure of Fairbanks (Fairbanks et al., 1971), which 
involves heating the polyacrylamide gels in staining buffers using a microwave. A total processing 
time of 20 minutes using this rapid procedure allows visualisation of as little as 5 ng of protein.
The gel was incubated in approximately 20 ml of Buffer A (25% 2-propanol, 10% acetic acid, 
0.05% Coomassie Blue) and heated in a microwave at high power for 30 seconds. Subsequently it 
was shaken for at least 10 minutes at RT. Buffer A was exchanged for Buffer B (10% 2-propanol, 
10% acetic acid, 0.005% Coomassie Blue) and the gel was heated again for 30 seconds in a 
microwave. Thereafter, no shaking was required and Buffer B was immediately exchanged by 
Buffer C (10% acetic acid, 0.002% Coomassie Blue). After additional heating as before, the gel 
was placed in Destaining Solution (10% acetic acid) O/N.
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2.4.5 Drying of SDS Gels
After destaining of the SDS gel, it was dried using the GelAir Drying Frame from BioRad. The gel 
was incubated in Gel-Drying Buffer (5% EtOH, 10% glycerol, 1 1 distilled H2 O) for about 30 
minutes and placed between two sheets of cellophane as recommended by the manufacturer. The 
gel was then dried at 28°C O/N.
2.4.6 Immunoblot analysis (Western blotting)
The Western blot was developed by Towbin and co-workers in 1979 (Towbin et al., 1979). It is the 
electrophoretic transfer of SDS-gel separated proteins onto a PVDF membrane (FluoroTrans, Pall, 
Ireland) where they can be detected by antibodies. A primary antibody is specific for the 
investigated protein, whereas the secondary antibody is specific for the primary antibody. An 
enzyme (in this case alkaline phospatase, PhoA) is fused to the secondary antibody, and when its 
substrate (BCIP/XP) is added, a colour change is detected which makes the desired protein band(s) 
visible.
The membrane was activated in 100% methanol for a few seconds and the blotting apparatus 
(BioRad Mini Trans-Blot® Cell) was assembled as recommended by the manufacturer. The electro­
transfer was carried out for 1 hour at 100 V in Transfer Buffer (15 mM TRIS, 120 mM glycine, 
20% methanol, 0.02% SDS). After the transfer, the membrane was stored between two 
Whatmanpapers (GB 003, Schleicher & Schuell, Germany) at RT.
For detection of the protein band(s) with specific antibodies, the membrane was blocked for at least 
1 hour at RT on a table-top shaker (or O/N at 4°C). Blocking was performed with 2% dry milk 
(Tesco, UK) or BSA (Fisher Scientific, UK) in TBST. Some antibodies, e.g. the mouse anti His-tag 
antibody require BSA as blocking reagent. Supsequently, the membrane was incubated in 10 ml 
TBS-T (20 mM TRIS pH 7.5, 150 mM NaCl, 0.05% TWEEN-20) with the appropriate
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concentration of primary antibody and placed on a table-top shaker for 1 hour. After the binding of 
the primary antibody to the investigated protein, the membrane was washed for 5 minutes (3 times) 
in 10 ml TBS-T. The membrane was then incubated in 10 ml TBS-T with the desired concentration 
of the secondary antibody for 30-60 minutes and the washing procedure was repeated as before. To 
detect the protein bands investigated, the membrane was incubated in 10 ml of Staining Solution 
(10 ml AP buffer [100 mM TRIS pH 9.5, 100 mM NaCl, 5 mM MgCl2], 66 |il NBT (50 mg/ml in 
70% DMF), and 33 pi BCIP (50 mg/ml in 100% DMF). To avoid further staining, the membrane 
was rinsed with tap water or it was incubated in 10 ml 5 mM EDTA for a few minutes.
2.4.6 PhoA (alkaline phosphatase) assays
To determine the PhoA activity of the Pen2-PhoA or the Aphl-PhoA hybrid proteins, an overnight 
culture of MC4100 containing the relevant plasmid was diluted 1/50 in NZA liquid medium 
containing 200 pg/ml Amp for about two hours. Subsequently, protein expression was induced by 
the addition of 0.1% Arabinose and the diluted culture was grown until O.D6 0 0  was about 0.3-0.6.
Of these cells, 0.2 ml was added to 0.8 ml washing buffer (10 mM Tris pH 8.0, 150 mM NaCl). 
The cells were gently vortexed and spun down in a table-top centrifuge. This washing step was 
repeated twice. 0.75 ml of the washed cells was used to determine O.D6oo* To perform the PhoA 
assay, 100 pi washed cells were added to 900 pi assay buffer (1 M Tris pH 8.0, 1 mM ZnCl), 25 pi 
0.1% SDS, 25 pi chloroform and were gently mixed and incubated at RT for 5 minutes. After 
adding 100 pi PhoA substrate buffer (1 M Tris pH 8.0, 0.4% pNPP [p-nitrophenyl phosphate]), the 
reaction was gently mixed and incubated at 28°C until colour was visible. The addition of 120 pi 
K2HPO4 stopped the reaction from proceeding further. Cells were spun down for 5 minutes in a 
table-top centrifuge and O.D420 of the supernatants was measured. The following formula was used 
to determine the PhoA activity of each hybrid protein:
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OD420 X 1000
PhoA activity (units) = ----------- --------------------------------------
Time (min) x OD6 0 0  x cell volume (ml)
2.4.7 p-Galactosidase (P-Gal) assays
To determine the level of interaction between different components of the y-secretase complex, p- 
Galactosidase Assays were carried out. MC4100 cells containing the relevant plasmids were grown 
O/N and then diluted 1/30 and grown for a further 1-2 hours. IPTG was used to induce protein 
expression and cells were grown for a further 2-3 hours until OD6 0 0  reached 0.3-0.7. Cells were 
washed twice in Z-Buffer (for 1 1 Z-buffer: 10.7 g Na2 HP0 4 .2 H2 0 , 5.5 g NaH2 P0 4 .H2 0 , 0.75 g 
KC1 pH 7.0 and 0.246 g MgS0 4 .7 H2 0 . 1 ml of cells in Z-Buffer was taken to determine OD6 0 0 , and 
another 1 ml in Z-Buffer was added to 50 pi 0.1% SDS and 50 pi CHCI3 , vortexed gently and 
incubated at room temperature for 5 minutes. To that, 0.2 ml ONPG (4 mg/ml in Z-buffer) was
added and incubated at 37°C or 28°C depending on the strain used in the assay. When colour
developed, the reaction was stopped by the addition of 0.5 ml 1 M N a^C ^. The samples were then
spun at high speed for 5 minutes to remove the cells. The O.D420 of the supernatants could be read
immediately, or the supernatants could be stored at 4°C overnight. As a reference, the following
was used: 1 ml Z-buffer, 50 pi 0.1% SDS, 50 pi CHCI3 , 0.2 ml ONPG and 0.5 ml 1 M Na2 C0 3 . The
following equation was then used to calculate P-Gal activity:
B-Gal-activity umol = AF.405 X Vt
mg X min OD578 X cP X VB X e
OD420
= 3.269 x ------------
OD5 7 8  X t
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t: reaction time
cP: protein conc. (107 pg protein / ml OD5 7 8 )
Vt: final volume of the assay (1.7 ml)
VB: volume of cells added to the assay
e: extinction coefficient of ortho-Nitrophenol at 405 nm (4860 M 'l)
2.4.8 Protein purification by FPLC (Fast Protein Liquid Chromatography)
FPLC was used to separate a protein from a protein mixture in solution. This method of 
chromatography takes advantage of the affinity of certain parts of a protein to a stationary phase 
e.g. the binding of a His-tag to a metal chelating column.The His-tag binds to positive metal ions 
including Ni2+, Co2+ and Cu2+. In this work, Ni NTA (Ni NTA superflow, Qiagen, Germany) was 
used as a stationary phase and packed into an empty column (XK 16, Amersham Pharmacia 
Biotech). Elution of His tagged proteins was performed by increased concentrations of imidazole, 
which competes with the His tags for the binding sites to the positive metal ions.
2.4.8.1 Growth of cells
For expression, double NZA containing the appropriate antibiotics was inoculated with a single 
colony and cells (200 ml) were grown to saturation overnight. The overnight culture was diluted 
1 / 2 0  in the same medium (4 1) and growth was maintained at 28°C until the O.D5 0 0  reached 
approximately 0.5. At this point, IPTG was added to a final concentration of 100. The culture was 
grown further at 20°C for 4 hours or overnight with shaking at 220 rpm.
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2.4.8.2 Harvest of cells
Cells from a 4 1 culture were harvested by centrifugation at 13,000 rpm for 10 minutes in a 
Beckman GSA centrifuge. The pellet containing the cells can be frozen at -20°C until required, or 
the cells can be resuspended in 200 ml of lysis buffer (50 mM Tris-HCl pH 8.0 300 mM NaCl).
2.4.8.3 Preparation of a cell lysate
This is performed either prior to membrane preparation, in the case of C99, or following the 
solubilisation of membrane proteins from whole cell extracts in the case of Pen-2. Cells in lysis 
buffer were disrupted by sonication for a maximum of 10 minutes or in a French pressure cell 3 
times at 15,000 psi. The cell lysate was cleared by centrifugation at 13,000 rpm for 10-30 minutes 
to remove unbroken cells and aggregates which should be present in the pellet. The supernatant is 
then used directly for purification of proteins by FPLC, or is used to prepare membranes.
2.4.8.4 Preparation of membranes
The supernatant was ultracentrifuged for 45 min at 45,000 rpm to sediment membranes. To wash, 
the membranes were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl) by 
homogenisation, and collected again by ultracentrifugation as described. The membranes were 
subsequently either used immediately or stored at - 20°C until protein solubilisation was performed.
2.4.8.5 Determination of protein concentration with bicinchoninicacid according to the sigma 
procedure TPRO-562
5 pi of pure protein, whole cell extract or membranes in a small volume of solubilisation buffer (20 
mM Tris-HCl pH 8.5, 300 mM NaCl) were added to 95 pi of solubilisation buffer. This 100 pi was 
then made up to 1 ml with BCA solution (1/50 buffer B/buffer A, as recommended by the 
manufacturer). As a control, solubilisation buffer in BCA solution (no protein) was used.
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Calibration was performed as recommended by the supplier and the O.D56 8 of each sample was 
read in a spectrophotometer.
Subsequently, the following equation was used to determine protein concentrations in pg/ml:
OP - 0.003703 
0.013841
2.4.8.6 Solubilisation of membrane proteins
For the solubilisation of membrane proteins like C99 and Pen-2, whole cell extracts or membrane 
suspensions were adjusted to a protein concentration of 2 to 2.5 mg/ml with the appropriate 
solubilisation buffer. Detergents like DDM, CHAPSO and SDS were used in a 1% concentration. 
The protein/detergent mixture was stirred on ice (or at RT for SDS) for 1 to 2 hours and 
subsequently ultracentrifuged for 45 minutes at 45,000 rpm. The supernatant, containing the 
solubilised proteins was then loaded on the Ni NTA column for chromatography.
2.4.8.7 Purification with a Ni NTA superflow column
The Ni NTA superflow was obtained from Qiagen, Germany. For a column volume of about 5 ml, 
10 ml Ni NTA was loaded onto an empty column, which was then connected to the FPLC 
according to the manufacturer’s instructions. The column was rinsed with distilled water with a 
flow rate of 3 ml/min to allow the Ni NTA material to settle. Afterwards, the column plunge was 
pushed down so it fitted directly above the level of material in the column. The column was washed 
with 5 to 10 column volumes (CV) of equilibration buffer (50 mM sodium phosphate buffer pH 8.0, 
300 mM NaCl). The protein solution was loaded on the column with a flow rate of 0.5 to 1 ml/min. 
Subsequently, the column was washed with 10 CV equilibration buffer to remove any excess 
proteins that did not bind to the column, and then washed with 10 CV equilibration buffer 
containing 10 to 30 mM imidazole to remove contaminants. The protein was eluted with ten CV 
elution buffer (50 mM sodium phosphate buffer pH 8.0, 300 mM NaCl and 500 mM imidazole).
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The flow rate for washing steps and elution was 2 ml/min.The Ni NTA was stored in 20% EtOH, 
and stripping and reloading was performed according to the manufacturer’s instructions.
2.4.9 y-Secretase assays
The following bacterial plasmids containing the individual human y-secretase components were 
transformed into the DegP minus strain KU98 (degPr.kan) pSAl (Pen-2), pSA12 (Aph-1), 
pSG6  (C99), pMH13 (PS-lAexon9) and pMH42 (NicA). Additionally the plasmids containing 
Y-secretase components (pSA14 (Pen-2 and Aph-1), pSG33 (PS-1) or pSG34 (PS-lAexon9), 
and pSG36 (NicA) were transformed into the strain KS272. Cells were grown, harvested and 
membranes prepared as described previously, and as a control, the cells KU98 or KS272 
containing no plasmids were treated similarly.
Membranes of KU98 or KS272 containing the y-secretase components Pen-2, Aph-1, PS- 
1 Aexon9 and NicA were re-suspended in a small volume of lysis buffer (50 mM Tris-HCl pH 
8.0, 300 mM NaCl) and the protein concentration of the membrane suspensions was measured 
using a BCA (bicinchoninic acid) protein determination kit. In the case of KU98 membranes, 
equal concentrations of each membrane suspension producing a different y-secretase component 
were mixed to a total concentration of 400 pg and a total volume of about 5 ml. The mixture 
was incubated at 37 °C for 24 h, and then the substrate C99 (produced in KU98 and purified by 
FPLC) was added in different concentrations. In the case of the KS272 membranes, 400 pg of 
membrane suspension was added to different concentrations of C99 and the mixture was 
incubated at 37 °C. As a control, membrane suspensions with no added substrate or with 
missing y-secretase components were used. 1 ml samples of the assay were removed at 0  hours, 
6  hours, 24 hours, 36 hours and 48 hours after the addition of substrate and the reaction was
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stopped by freezing the samples at -20°C. The samples were then analysed using an Ap ELISA 
kit from the Genetics Company and by Western blotting, to detect levels of Ap produced.
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(3) CLONING, EXPRESSION AND TOPOLOGICAL STUDIES OF 
THE HUMAN y-SECRETASE COMPONENTS IN E. COLI
3.1 Introduction
The y-secretase pathway, as illustrated in chapter (1), represents the proteolytic cascade that leads 
to the development of Alzheimer’s disease in the human brain. The y-secretase complex is now 
thought to be comprised of four cytoplasmic membrane proteins, including Presenilin-1 (PS-1) 
which is postulated to form the active site of the complex. The other components are Nicastrin 
(NicA), Aph-1 and Pen-2. Following the cleavage of APP by p-secretase, the C-terminal fragment 
of APP (C99) which contains AP, remains in the membrane. C99 is then processed by the y- 
secretase complex in a final cleavage step, producing the highly fibrillogenic Ap4 o or Ap4 2  peptides. 
PS-1, NicA, Pen-2 and Aph-1 have been shown to constitute the minimum components required for 
y-secretase activity in a number of different cell types including C. elegans and D. melanogaster, 
but these data do not rule out the involvement of other factors. Therefore, we suggest that a simpler 
system is required for verification and we propose using E. coli as a model system. E. coli have a 
simple genome which is evolutionary very different from that of higher eukaryotes. This suggests 
that E. coli are unlikely to contain co-factors for the y-secretase, and that they could represent the 
ideal system for studying the y-secretase components’ functions and interactions. Overproducing 
the y-secretase in E. coli could allow future analysis and purifications of the complex members, 
including the possibility of performing controlled enzyme assays.
The production of recombinant human proteins in E. coli can be problematic, especially membrane 
proteins. A common reason for limited overproduction of membrane proteins is degradation by
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cellular proteases. For this reason, the strain KU98 (Section 2.2.1, Materials and Methods), which 
lacks degP was chosen for most overproduction studies. Deletion of such proteases was thought of 
as beneficial as it may result in increased stability of the recombinant proteins. In addition, a 
suitable vector such as pGRDl 1 and pCS19 (Section 2.3.1, Materials and Methods) was chosen for 
cloning the genes encoding the y-secretase components. In these vectors, expression is under 
control of the tac promoter which is inducible by IPTG or lactose, therefore all E. coli strains 
containing these plasmids were grown in lactose-free media such as NZA. The vectors pGDRl 1 
and pCS19 contain an optimal Shine Dalgamo sequence for improved translation, a multiple 
cloning site, the bla sequence which encodes the Ampicillin (Amp) resistance gene and the lac 
repressor {lacfi) is over-expressed to ensure tight promoter control. The presence of an N- or a C- 
terminal His-tag is useful as it will allow detection of protein expression levels by using a 
monoclonal a-poly histidine antibody, and future purifications via nickel or copper 
chromatography.
As we are dealing with human membrane proteins in an E. coli system, it was important to ensure 
correct insertion of the recombinant proteins into the bacterial cytoplasmic membrane. In theory, 
any region of about 2 0  hydrophobic amino acid residues corresponds to a transmembrane helix 
(Kyte and Doolittle, 1982) and therefore, the amino acid sequence of any protein can be used to 
predict its transmembrane segments. The topology of integral cytoplasmic membrane proteins in E. 
coli can be studied in vivo by a genetic approach developed in the late eighties, which involves 
generating hybrids of the target membrane protein to PhoA (Manoil and Beckwith, 1986; Manoil et 
al., 1990). In wild-type strains, PhoA is only active after being exported to the periplasm where its 
disulphide bonds can be formed as a result of the oxidising environment in the periplasm (Derman 
and Beckwith, 1991). Periplasmic domains of integral membrane proteins can be fused to signal 
sequenceless PhoA that is then properly translocated (Manoil and Beckwith, 1986). When PhoA is
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fused to a cytoplasmic domain it is enzymatically inactive. Therefore, the activity of phoA fusions 
is used to predict the cellular localisation of the fused membrane protein domain (Boyd et al., 1993; 
Ehrmann, et al., 1990). Here, we constructed Pen-2-PhoA, Aph-1-PhoA hybrids and described 
previous construction of PS-1-PhoA hybrids (Hamasch, 2003). Individual fusion joints were placed 
at the C-termini of hydrophilic regions of the membrane proteins. Boyd and co-workers introduced 
this experimental strategy in order to minimise the disruption of topological signals (Boyd et al., 
1993).
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3.2 Cloning and expression of the human y-secretase components. and the y- 
secretase substrate, c99. in E. coli
3.2.1 Cloning and expression of pen-2 and aph-1 in different combinations
3.2.1.1 Cloning pSAl containing pen-2 andpSA2/12 containing aph-1
pen-2 and aph-1 were amplified by PCR from a lambda-zap-cDNA library (Klostermann et al., 
2000) from neuronal cell cultures. In order to produce the proteins, each gene was cloned into a 
suitable vector for expression studies. To aid detection of the produced proteins, it was thought 
useful to clone the genes with a His-tag that can be detected with a monoclonal a-penta histidine 
antibody (Qiagen, Germany). Moreover, the His-tag allows future purification of the proteins via a 
nickel or copper chromatography column. Human pen-2 and aph-1 were cloned into the E. coli 
expression vector pGDRll where an N-terminal His-tag is encoded by the 5’ end of the multiple 
cloning site.
The gene pen-2 was amplified from the cDNA library using the oligonucleotides “pen2-5'(BamHI)” 
and “peri2-3'(KpnI)”, while aph-1 was amplified using the oligonucleotides “AphI/A/?«//pGDRl 1” 
and “AphI////m/////pGDRl 1” (Section 2.3.2, Materials and Methods) which resulted in PCR 
products with flanked restriction sites. The vector pGDRl 1 was prepared via restriction digestion, 
and the PCR products were ligated into the multiple cloning site of the vector via BamHI/Kpnl and 
HindHI/Kpnl for pen-2 and aph-1 respectively (Figure 3.1). The ligation reactions were then 
transformed into electrocompetent MC4100 cells (Section 2.2.1, Materials and Methods) and 
transformants were used to prepare plasmid DNA of the candidates for pSAl and pSA2. 
Candidates were then confirmed by restriction digestion and analysed by agarose gel 
electrophoresis. Sequencing of both inserts excluded the presence of mutations in the pen-2 
sequence of pSAl, but revealed a frameshift mutation in the aph-1 sequence in pSA2 as a result of
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an extra Cytosine at the 3’ end of the gene (C728). It was thought that this may affect protein 
structure and function, therefore a new plasmid was constructed containing wild-type aph-\. In this 
case, aph-1 was amplified in the same way (Figure 3.1), but from the plasmid pCDNA (zeo) 
Aphla251, obtained from the Haass laboratory, Munich. This resulted in the construction of the 
plasmid pSA12, which contains wild-type aph-1 with an N-terminal his tag.
It was not until later on it was revealed that the aph-1 gene in the cDNA library obtained from 
Klostermann and co-workers, was in fact a naturally occurring splice variant of aph-1 (See Swiss- 
prot).
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pGDRllColEl originbla
BamHI
PTac & His tag
Kpnl Hindlll
 1
 |
BamHI Kpnl 
-------- aph-1 PCR 
product
pen-2 PCR 
product
pSAlCol El originbla
BamHI
pSA2/12Col El originaph-Ibla
Figure (3.1) Schematic representation of the construction of pSAl and pSA12 containing 
human pen-2 and aph-1 respectively, both with N-terminal His tags.
The genes were amplified from a lambda-zap-cDNA library from neuronal cell cultures, and in the case o f pSA12,
from the plasmid pCDNA (zeo) Aphla251. The genes were cloned into the multiple cloning site o f  pG D R ll via 
BamHI and Kpnl for pen-2, and Kpnl and Hindlll for aph-1. This resulted in the fusion of the genes to an N-terminal 
His-tag. The genes are IPTG inducible, the Lac repressor (lac ft) ensures a tight promoter, and bla encodes P-lactamase 
conferring Amp resistance.
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3.2.1.2 Cloning pSA ll, containing tag-less pen-2
After the construction of pSAl containing pen-2 with an N-terminal His-tag, we learnt that 
alteration of the N-terminus of Pen-2, e.g. by the addition of an N-terminal His-tag may alter its 
topology and therefore its activity. The cellular localisation of the N-terminus of Pen-2 cannot be 
readily predicted. If it is in the periplasm, the addition of 6  histidine residues to the N-terminus may 
alter the topology of Pen-2 and therefore its activity. Consequently, a new plasmid was constructed, 
pSA ll, which contained pen-2 without a His-tag. Human pen-2 was cloned into the E. coli 
expression vector pCS19 (Section 2.3.1, Materials and Methods) where a C-terminal His-tag is 
normally encoded by the 3’ end of the multiple cloning site, but which was deleted in this case. 
Similarly to pGDRl 1, pCS19 contains a lacfi, an optimal Shine Dalgamo sequence and bla which 
encodes p-lactamase conferring Amp resistance.
The gene pen-2 was amplified from pSAl using the oligonucleotides “pen2-5'(iVco/)” and “pen2- 
3'(Hindlll)” (Section 2.3.2, Materials and Methods) which resulted in PCR products with flanked 
restriction sites. The vector fragment of pCS19 was prepared via restriction digestion, and the PCR 
products were ligated into the multiple cloning site of the vector via Ncol!Hindlll (Figure 3.2). The 
ligation reactions were then transformed into electrocompetent MC4100 cells, and transformants 
were used to prepare plasmid DNA of the candidates for pSAl 1. Candidates were then confirmed 
by restriction digestion and analysed by agarose gel electrophoresis. Sequencing of the insert 
excluded the presence of mutations in the pen-2 sequence.
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pCS19ColSl originbla
Ncol
His tagPTae
Hindlll Ncol
pen-2 PCR 
product
pSA llpen-2 ColSl originbla
Ncol
Figure (3.2) Schematic representation of the construction of pSAl 1 containing tag-less pen-2.
The gene was amplified from pSAl, and ligated into the multiple cloning site o f  pCS19 via HindlH/NcoI deleting the
C-terminal his tag and resulting in tag-less pen-2. The gene is IPTG inducible, the Lac repressor (lacfi) ensures a tight 
promoter, and bla encodes P-lactamase conferring Amp resistance.
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3.2.1.3 Expression ofpen-2 from pSAl and pS A ll, and aph-1 from pSA2 and pSA12
To determine whether the cloned plasmids expressed pen-2 and aph-1, the strain KU98 was 
transformed with either pSAl, pSA2, pS A ll or pSA12 via TSS transformation (Section 2.3.8.1, 
Materials and Methods). Subsequently, KU98 containing these plasmids was grown in 5 ml NZA 
medium containing 200 pg/ml Amp, overnight. The cultures were diluted 1/50 in the same medium 
and allowed to grow until the OD6 0 0  reached approximately 0.5. The expression of each of pen-2 
and aph-1 in pSAl and pSA2 respectively, is controlled by the tac promoter, which is IPTG 
inducible. Therefore, the cultures at log phase were induced with 100 pM IPTG and samples were 
removed after growth at 28 °C for 4 hours.
To investigate if the presence of other y-secretase components like PS-1, and the y-secretase 
substrate C99 will have any effect on the expression levels of pen-2 and aph-1, the strain KU98 
containing one of pSAl, pSAl 1, pSA2 or pSA12 in addition to pSG33 (containing ps-1 and c99 in 
a pACYC derivative) was also grown as above. Expression in pSG33 is also under the control of 
the tac promoter and can therefore be induced by IPTG. Gene expression was induced by the 
addition of 100 pM IPTG and samples were removed after growth at 28°C for 4 hours. As a 
negative control, each strain containing the different combination of plasmids was also grown as 
before, but no IPTG was added to induce protein expression, and therefore little or no protein 
should be detected after analysis with a Western blot.
Whole cell extracts were prepared by removing 1 ml of induced culture of each sample and 
centrifuging it at 13,000 rpm in a table top centrifuge, followed by the addition of sample buffer to 
adjust the O.D. of the samples. Protein samples were loaded on 15% SDS gels as both Pen-2 and 
Aph-1 are very small, and Western blots were performed using a monoclonal a-penta histidine
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antibody (Sigma) for the detection of Aph-1, and a polyclonal a-Pen-2 antibody (Haass laboratory, 
Germany) for the detection of Pen-2.
Western blotting revealed that both Pen-2 and Aph-1 are produced in reasonably large amounts 
from pSAl and pSA ll for Pen-2 and pSA2 and pSA12 for Aph-1 (Figure 3.3). In addition, co­
expression of ps-1 and c99 with pen-2 and aph-1 did not facilitate increased production of neither 
Pen-2 nor Aph-1, and in some instances, it even resulted in reduced production levels of the 
recombinant proteins. Also in this instance, expression of pen-2 without a his tag (pSAll) was 
higher than that of his tagged pen-2 but this result was not replicated and therefore from then on, 
pSAl was generally used for studies of Pen-2.
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Figure (3.3) Western blot monitoring the expression of pen-2 from pSAl and pS A ll, and the
expression of aph-1 from pSA2 and pSA12
The strain KU98 was transformed with each of the following combinations of plasmids by TSS transformation: (A)
pSAl, pSAl and pSG33, p S A ll, pSA ll and pSG33, and (B) pSA2, pSA2 and pSG33, pSA12, pSA12 and pSG33. 
KU98 containing the plasmids was grown overnight at 28°C and then diluted 1/50 and grown again until O.D60o 
reached about 0.5. Subsequently, expression was induced by the addition of 100 pM IPTG to the cultures at log phase. 
Un-induced samples were used as negative controls. The samples were then analysed by SDS gel electrophoresis and 
Western blotting using a monoclonal a penta histidine antibody from Sigma. Molecular weights are given in kDa.
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3.2.1.4 Pen-2 expression is stable after overnight induction
KU98 was transformed with the following combination of plasmids via TSS transformation: pSA l, 
p S A ll, pSG33, pSAl and pSG33 or pS A ll and pSG33. Single colonies were used to inoculate 
NZA medium containing the appropriate antibiotics (Amp for pSAl and Cm for pSG33) and the 
cultures were grown overnight at 28°C. The following day, the overnight cultures were diluted 1/50 
in the same medium and left to grow at 28°C until OD600 reached approximately 0.5. The cells at 
log phase were then induced by the addition of 100 pM IPTG and the induction was carried out for 
4 hours and overnight. The samples were analysed by SDS PAGE and Western blotting using a 
polyclonal a pen-2 antibody (Haass Laboratory, Germany). The Western blot, as before revealed 
that the co-expression of other y-secretase components like ps-1 and c99 does not increase 
expression of pen-2 nor does it stabilize the protein produced. The blot (Figure 3.4) also showed 
that pen-2  alone, is expressed in sufficient amounts, and that it is stable on its own after O/N 
induction. KU98 containing pSG33 (ps-1 and c99) was used as a negative control.
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Figure (3.4) Western blot monitoring overnight expression of pen-2 in KU98
KU98 cells transformed with either pSAl, pSAl 1, pSAl with pSG33, pSAl 1 with pSG33 or just pSG33 as a control
were grown to log phase and then induced with 100 pM IPTG. Samples were analysed by SDS PAGE and Western 
blotting using a polyclonal antibody directed against the C-terminus of Pen-2. Molecular weights are given in kDa.
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3.2.1.5 Construction of pSA13 and pSA14 containing pen-2 and aph-1 both with N-terminal 
6xhis tags
It was recently demonstrated that Pen-2, Aph-1, PS-1 and NicA represent the minimal set of 
components required for y-secretase activity. E. coli represents an excellent system for 
reconstituting this activity because in contrast to eukaryotic cells and higher organisms, it contains 
no endogenous proteins that may interfere with the activity in question. One technique for 
reconstituting y-secretase activity is to combine all four components in the one E. coli strain. The 
four proteins comprising the y-secretase complex can then be produced and an enzyme assay can be 
carried out by the addition of the y-secretase substrate C99, followed by the determination of the 
amount of Ap produced by, for example, ELISA. Alternatively, the presence of PS-1 N- or C- 
terminal fragments, or the reduction in the amount of substrate, C99, can be detected by Western 
blotting.
Given the plasmids available in the laboratory collection, there are a number of origins of 
replication and antibiotic resistances, we were unable to construct a strain that could accommodate 
more than three plasmids simultaneously. Therefore it was thought necessary to combine some of 
our investigated genes by cloning them into the same plasmids, ps-1 and c99 were already present 
on the same plasmid, pSG33 (Grau, 2004), likewise in this chapter, the combination of pen-2 and 
aph-1 is described. Figures 3.1 and 3.2 can be used as references.
The aph-1 gene was amplified by PCR from the plasmid pSA12 (Section 2.3.1, Materials and 
Methods) using the oligonucleotide “SDpGDRl MSalF for the forward reaction and 
“AphI////«<7////pGDRl 1 nones” for the reverse reaction (Section 2.3.2, Materials and Methods). 
This resulted in a fragment containing aph-1 with the flanked restriction sites Sail and Hindlll. The 
vector pSAl, containing pen-2 with an N-terminal His-tag was prepared via restriction digestion
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with the same restriction enzymes. The aph-1 PCR product was then ligated into the vector, the 
ligation reactions were transformed into electrocompetent MC4100 cells, and transformants were 
used to prepare plasmid DNA of the candidates for pSA14. Candidates were confirmed by 
restriction digestion and analysed by agarose gel electrophoresis. Sequencing of the insert excluded 
the presence of mutations in the aph-1 sequence. The same procedure was repeated using pSA2 
instead of pSA12 and this resulted in the plasmid pSA13, containing the splice variant of aph-1 
with pen-2, both with N-terminal his tags.
3.2.1.6 Pen-2 and Aph-1, are produced in E. coli from pSA13 and pSA14
To determine whether the cloned plasmids expressed pen-2 and aph-1, pSA13 and pSA14 
containing both pen-2 and aph-1 with N-terminal His tags, were transformed into KU98. Single 
colonies were used to inoculate NZA medium containing 200 pg/ml Amp and cultures were grown 
to saturation overnight at 28°C. Cultures were then diluted 1/50 in the same medium and grown 
until the O.D6 0 0  reached approximately 0.5. The cells at log phase were then induced by the 
addition of 100 pM IPTG and the induction was carried out for 4 hours. The samples were analysed 
by SDS PAGE and Western blotting using a monoclonal a-penta histidine antibody from Sigma.
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Figure (3.5) Western blot monitoring pen-2 and aph-1 expression from the plasmids pSA13
and pSA14
KU98 containing either pSA13 or pSA14 was grown at 28°C to an O.D600 of approximately 0.5. Gene expression was 
then induced for 4 hours by the addition o f 100 pM IPTG. The samples were analysed by SDS PAGE and Western 
blotting using a monoclonal a-penta histidine antibody from Sigma. Un-induced samples were used as controls, and 
molecular weight standards are given in kDa.
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3.2.2 Cloning and Expression of C99, PS-1 and NicA
This work was performed during previous PhD projects carried out at the Ehrmann laboratory, 
Cardiff University.
Sandra Grau (PhD thesis, 2004) cloned the human c99 into the E. coli expression vector pCS19 
producing the new construct pSG6 (Section 2.3.1, Materials and Methods) containing c99 with a 
C-terminal His-tag. For expression studies, pSG6 was transformed into the strain KU98 and gene 
expression was induced with 10 pM IPTG for 4 hours and overnight. SDS PAGE and Western 
blotting using a a-penta histidine antibody, showed that human C99 is produced in E. coli and 
that it is stable after induction for 4 hours but it is degraded overnight at 28°C.
Mona Hamasch (PhD thesis, 2003) cloned and expressed nicA, ps-1 and the gain of function 
mutant ps-lAexon9 which has been shown to have a role in early onset familial Alzheimer’s 
disease (FAD). Human ps-1 and ps-lAexon9 were cloned into the E. coli expression vector 
pGD Rll, resulting in pMH12 and pMH13 containing ps-1 and pslAexon9 respectively, both 
with N-terminal His-tags. For expression studies, pMH12 and pMH13 were transformed into a 
number of strains including KU98. It was shown that in KU98, induction of gene expression 
with 100 pM IPTG resulted in the production of human PS-1 and PS-lAexon9 in E. coli. It was 
found that at a high concentration the proteins migrated as a smear on SDS gels probably 
because of their hydrophobicity, but it was found that diluting the samples can aid the 
appearance of more distinct bands, which were verified by Western blotting using antibodies 
directed against the N-terminus of PS-1. The proteins were also stable after induction for 4 hours 
and overnight at 28°C in KU98. Human nicA was cloned into the E. coli vector pASK-IBA2 
(Section 2.3.1, Materials and Methods) resulting in pMH42 containing nicA with a C-terminal 
StrepII-tag. For nicA expression, pMH42 was transformed into KU98 and gene expression was
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induced with 100 nM A-tet for 3 hours. This revealed that human NicA can be produced in E. 
coli after induction for 3 hours at 28°C.
3.3 Topological studies of the human y-secretase components in E. coli
Before any further studies can be performed with any of the y-Secretase components, it is important 
to ensure that the human membrane proteins have reached their correct compartment in E. coli and 
that they are properly inserted into the bacterial cytoplasmic membrane.
3.3.1 Determining the topology of human Pen-2 and Aph-1 in the E. coli membrane
3.3.1.1 Construction of pen-2- and aph-1-alkaline phosphatase (phoA) fusions
To investigate the topology of Pen-2 and Aph-1 in E. coli, Pen-2-PhoA and Aph-1-PhoA hybrid 
proteins were constructed. PhoA is only active when it is translocated to the periplasm, where 
oxidising conditions allow its disulfide bonds, which are essential for its structure and therefore 
function, to be formed. The fusion of signal sequenceless phoA to appropriate pen-2 or aph-1 
fragments aids determination of the localisation of the fusion joint of each Pen-2-PhoA or Aph-1 - 
PhoA hybrid protein. High PhoA activity indicates a periplasmic localisation whereas low PhoA 
activity indicates a cytoplasmic localisation.
From their amino acid sequences, Pen-2 and Aph-1 were thought to have two and six TM segments 
respectively. Appropriate pen-2 (1-2) and aph-1 (1-6) fragments were amplified by PCR from the 
plasmids pSAl and pSA2, using the “universal-fw-Awa/ (Pen-2)” and “universal-fw-Ama/ (Aph- 
1)” oligonucleotides for the forward PCR reaction for each of the pen-2 and aph-1 fragments 
respectively. The corresponding N-Xbal-rev” oligonucleotide appropriate for each fragment was 
used for the reverse reaction. For a list of oligonucleotide sequences refer to section (2.3.2) in
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Materials & Methods. These oligonucleotides were selected so that fragments ended directly in 
front of the predicted TM-segments (Figure 3.9).
Pen-2 amino acid sequence
MNLERV SNEEKLNLCRK Y Y LGG F A F L P F L WL VN1F W F FREAFL VPA YTEQ
60 101 4|
SOIKGYVWRSAVGFLFWVIVLTSWITIFOIYRPRWGALGDYLSFTIPLGT
Aph-1 amino acid sequence
H  30
MGAAVFFGCTFVAFGPAFALFLITVAGDPLRV11LVAGAFFWLVSLLLAS
VVWF1L V HVTDRSDARLOYGLL1FGAAVSVLLOEVFRFAYYKLLKKADEG
< | 116
LASLSEDGRSP1SIROMAYVSGLSFG11SGVFSVINILADALGPGVVGIH
4 | 154 4 |  186
GDSPYYFLTSAFLTAA11LLHTFWGVVFFDACERRRYWALGLVVGSHLLT
<1 213 251 < |
SGLTFLNPWYEASLLP1YAVTVSMGLWAFITAGGSLRSIORSSCVRTDYFD
Figure (3.6) Amino acid sequence of Pen-2 and Aph-1.
Putative transmembrane regions are shown in red and are underlined, and the blue arrows indicate the positions o f
PhoA fusion joints to each o f the transmembrane segments. The numbers o f amino acids at the fusion joints are also 
shown.
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The amplified fragments containing an Xbal site at the 5’ and an Xm al site at the 3’ end were 
cloned into the vector pEDIE3 upstream of phoA using these restriction sites. pEDIE3 has the 
arabinose promoter pBAD, an optimal translation initiation signal, a polylinker followed by signal 
sequenceless phoA. This resulted in the new plasmids pSA3 and pSA4 containing pen -2 fragments 
1 and 2 respectively, and plasmids pSA5 to pSAlO containing aph- 1 fragment 1 to fragment 6 
respectively (Figure 3.7). Constructs (pSA3-pSA10) were controlled by digestion with suitable 
restriction enzymes and were analysed by agarose gel electrophoresis. Sequencing o f all fragments 
ruled out the presence o f mutations.
3.3.1.2 Expression o f  pen-2-phoA and aph-l-phoA fusions
To test whether the cloned plasmids pSA3-10 produced the Pen-2 or Aph-1-PhoA fusions, the 
strain DHB4 was transformed with the afore-mentioned plasmids via electroporation. The resulting 
strains were grown at 37°C to log phase, induced with 0.1% arabinose and then subjected to SDS 
PAGE and Western blotting, using a monoclonal a-PhoA antibody (Caltag Laboratories, Canada). 
The expected sizes of the PhoA fusion proteins are listed in tables (3.1) and (3.2) below.
Pen-2 60 55.91
Pen-2 101 65.77
Table (3.1) Expected molecular weights of constructed Pen-2-PhoA fusion proteins
Aph-1 30 51.58
Aph-1 116 61.21
Aph-1 154 64.92
Aph-1 186 68.73
Aph-1 213 71.70
Aph-1 251 75.85
Table (3.2) Expected molecular weights of constructed Aph-l-PhoA fusion proteins
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Pen-2-PhoA fusions were shown to be produced and were stable after induction for 4 hours and 
overnight. However, Pen-2-PhoA fragment 1 which was encoded by pSA3 and postulated to have 
the fusion joint in the cytoplasm showed almost undetectable expression levels (Figure 3.8 C and 
D). Aph-1-PhoA fragments 1, 3 and 5 which were encoded by pSA5, pSA7 and pSA9 respectively 
were all expressed and were stable after induction for 4 hours and overnight. However, Aph-1 - 
PhoA fragments 2, 4 and 6 which were encoded by pSA6, pSA8 and pSA9 respectively could not 
be detected by the a-PhoA antibody. This is common behaviour for membrane protein-PhoA 
hybrids that have PhoA translocated to the cytoplasm. This results in a misfolded proteolytic 
domain and protein removal by cellular proteases. Therefore, the protein hybrids could not be 
detected.
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Xmal Xbal
Origin o f replication bla
Para AssphoA
(A) pEDIE3
Cloning o fpen-2 and 
aph-l fragments into 
pEDIE3 via 
* XmallXbal
Pen-2
Cytoplasmic
membrane
Cytoplasm
pen-2laph-l fragments 1-2 and 1-6 
Xmal \  I /X b a l
Origin of replication
P ara
bla
________
AssphoA
(C) pSA3-10
Figure (3.7) Schematic representation showing the cloning of pen-2 and aph-1 fragments into
pEDIE3.
(A) Is the empty vector pEDIE3, which has an arabinose promoter (Para) and signal sequenceless phoA (Jss phoA) 
preceded by the multiple cloning site. (B) Diagram o f Pen-2 and Aph-1 showing their predicted transmembrane 
segments. The positions o f the PhoA fusion joints are shown in red. (C) Cloning o f  pen-2 and aph-1 fragments into 
PEDIE3 via XbaHXmal to generate plasmids pSA3 and pSA4 for pen-2-phoA fragments 1 and 2 respectively, and 
plasmids pSA5 to pSAlO containing aph-l-phoA fragments 1 to 6 respectively.
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Figure (3.8) Western blots monitoring the expression of pen-2-phoA and aph-l-phoA  fusions.
(A) and (B): Lanes 1-6 contain Aph-1-PhoA fusions 1-6 respectively. Only TM segments 1, 3 and 5 seem to be
expressed after 4 hours or O/N induction. (C) and (D): Lanes 1-2 contain Pen-2-PhoA fusions 1-2 respectively. Both 
fusions seem to be expressed in this case, although the level o f expression of fusion 1 was very low. All plasmids 
(pSA3-10) containing pen-2-phoA or aph-1 -phoA fusions were transformed into the strain DHB4 and cultures were 
grown to log phase and induced with arabinose for 4 hours and O/N. Samples were analysed by SDS PAGE 
electrophoresis and Western blotting and the proteins were detected with an a-PhoA antibody. Molecular weights are 
given in kDa.
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3.3.1.3 PhoA activity of PhoA domains of Pen2-PhoA and Aph-1-PhoA hybrid proteins
To determine the cellular localisation o f the PhoA domain of Pen-2-PhoA and Aph-1-PhoA hybrid 
proteins in E. coli, we performed PhoA assays o f DHB4 containing the pEDIE3 derivatives, pSA3 
to pSAlO (Tables 3.1 and 3.2) according to the protocol in section 2.4.6, Materials and Methods. If 
each hydrophobic region of Pen-2 and Aph-1 is actually a TM-segment, PhoA activity for the 2 
different Pen-2-PhoA hybrid proteins and the 6 different Aph-1-PhoA hybrid proteins should 
alternate between high and low activity. As shown in tables 3.1 and 3.2, the expected PhoA activity 
values agree with those measured, which suggests that both Pen-2 and Aph-1 have the correct 
topology in E. coli with the C- and N-termini o f Pen-2 in the periplasm and those o f Aph-1 in the 
cytoplasm.
60 Low 7
100 High 21
Table (3.3) PhoA Activities of Pen-2-PhoA fusions
30 High 11
116 Low <1
154 High 16
186 Low <1
213 High 16
251 Low <1
Table (3.4) PhoA activities of Aph-l-PhoA fusions
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3.3.2 Determining the topology of PS-1 in the E, coli membrane
Similarly, Mona Hamasch (PhD thesis, 2003) investigated the topology of human PS-1 in the E. 
coli membrane by constructing Pho-A fusions with different PS-1 fragments (Figure 3.9). PS-1 has 
always been described as an eight transmembrane domain protein (Li et al., 1997), however, Kyle 
and Doolittle hydropathy blots have revealed an extra hydrophobic region at the very C-terminus of 
the protein. Therefore, ten PS-1-PhoA hybrid proteins were constructed to verify the topology of 
the PS-1 expressed in E. coli and to investigate the possibility of a ninth transmembrane segment. 
This resulted in plasmids pMH2 to pMHl 1, containingps-l-phoA  fusions 1 to 10 respectively.
For expression studies pMH2 to pM H ll were transformed into the strain KU104 (Section 2.2.1, 
Materials and Methods), and gene expression was induced by the addition of 0.2% arabinose for 3 
hours. Whole cell extracts were then analysed by SDS PAGE and Western blotting using a a-PhoA 
antibody (Caltag Laboratories, Canada). All ps-l-phoA  hybrids were expressed in E. coli. PhoA 
assays were also performed with the PS-1-PhoA hybrid proteins to reveal the cellular location of 
the PS-1-PhoA fusion joints. The PhoA assays yielded results which were consistent with the eight 
transmembrane segment model of PS-1, but indicated the presence of a ninth transmembrane 
segment at the very C-terminus of the protein (Hamasch et al., 2004).
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Periplasm
Cytoplasm
COOH
Figure (3.9) Schematic representation of PS-1.
The diagram shows the predicted transmembrane segments, and the PhoA fusion joints are indicated in red.
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3,4 Chapter Discussion
3.4.1 The human y-secretase components, and C99, are expressed in E, coli
It is now thought that Pen-2, Aph-1, PS-1 and NicA are the minimal components required for y- 
secretase activity. The roles of each of these proteins in bringing about y-secretase activity are still 
unclear, therefore producing these proteins in a simple system such as E. coli will prove useful in 
determining their functions and interactions. Producing polytopic membrane proteins in E. coli has 
always proved very difficult. However, heterologous expression has several advantages such as the 
absence of eukaryotic homologues, splice variants and interaction partners. In addition, the 
bacterial system allows convenient modification and purification approaches.
Here, we cloned the human genes pen-2 and aph-1 into an E. coli vector and produced the 
recombinant proteins in E. coli cells. Both proteins were produced in E. coli after 4 hours of 
induction with IPTG and Pen-2 was found to be stable overnight. Aph-1 was not detected after 
overnight induction which was probably due to degradation by E. coli proteases (Data not shown). 
It was thought that the presence of other y-secretase components such as PS-1 and the y-secretase 
substrate C99, may aid the stability of Aph-1 or increase the amount of Pen-2 and Aph-1 produced 
in the bacterial cells, but this was not found to be the case. The gain of function mutant PSlAexon9 
was found to be involved in FAD and therefore co-expressing this protein with Pen-2 or Aph-1 in 
the future may yield the expected result. Additionally, the level of Aph-1 expression from pSA13 
and pSA14 at 28°C was found to be low and the growth of KU98 cells containing any plasmids 
containing aph-1 was found to be very slow. Therefore, future expression of Aph-1 from these 
plasmids for the purposes of e.g. enzyme assays, were performed at 20°C because it appeared that 
producing Aph-1 at higher temperatures was stressful for the cells.
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As mentioned before, it was important to combine some of the y-secretase components in the same 
plasmids to allow their combined expression in one E. coli strain for the purpose of performing y- 
secretase assays. As we were uncertain about what the best combinations of Pen-2 and Aph-1 
would be and how the presence of N- or C-terminal His-tags will affect gene expression or protein 
topology, function and activity, more plasmids were constructed containing different combinations 
of pen-2 and aphl. One of the plasmids constructed was pSA16 containing tag-less pen-2 and aph- 
1 with an N-terminal His-tag. This plasmid can also be used for co-purification studies as Aph-1 
can be purified with a Ni2+ or Cu2+ column and the behaviour of Pen-2 could be observed. Also, as 
another alternative for the combination of pen-2 and aph-1, pSA18 was constructed which contains 
pen-2 and aph-1 with no His-tags.
3.4.2 The human y-secretase components are correctly inserted into the bacterial 
cytoplasmic membrane
There is a large body of evidence that suggests that the rules and signals that determine membrane 
insertion of complex integral cytoplasmic membrane proteins are conserved between species (van 
Geest and Lolkema, 2000). However, it is still important to ensure correct insertion of human 
membrane proteins into the E. coli membrane, as that represents an important step towards 
functional expression in bacteria. A genetic approach that involves using gene fusions to determine 
topology has been developed by Beckwith and co-workers and has been successfully used to 
determine the topology of over 100 integral cytoplasmic membrane proteins in E. coli. Originally 
constructed for topology studies of bacterial membrane proteins, the phoA fusion method was also 
successfully utilised for recombinant human membrane proteins in E. coli, such as the human beta 
2-adrenergic receptor (7 TM-segments), the human vasopressin V2 receptor (7 TM-segments), 
cyclic nucleotide-gated ion channels (6 TM-segments) and human presenilin-1 (8/9 TM-segments) 
(Hamasch, 2003; Henn et al., 1995; Lacatena et al., 1994; Schulein et al., 1996). Here, we show
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that the same technique can be used to determine the topology of human Pen-2, Aph-1 and PS-1 in 
E. coli.
To determine the topology of Pen-2 and Aph-1, eight plasmids were constructed (pSA3 to pSAlO) 
that contain fusions of pen-2 or aph-1 fragments to signal sequenceless phoA. The nucleotide 
sequence of Pen-2 has indicated that it probably has two TM-segments, and that both its N- and C- 
termini are in the periplasm. Whereas the nucleotide sequence of Aph-1 has indicated that it 
probably has 6 TM-segments and that both its N- and C-termini are in the cytoplasm. Expression of 
the gene fusions in pSA3 and pSA4 (corresponding to fusions 1 and 2 respectively) produced the 
Pen-2-PhoA hybrid proteins and they appeared to have approximately the molecular weight 
expected (Figure 3.11). However, the Pen-2-PhoA fusion 1 was not expressed as well. This could 
be due to the fact that this fusion joint resides within the cytoplasm and is therefore degraded by 
cellular proteases. Expression of the gene fusions in pSA5, pSA7 and pSA9 (corresponding to 
fusions 1, 3 and 5 respectively) produced the Aph-1-PhoA hybrid proteins and they appeared to 
have approximately the molecular weight expected. However, the gene fusions in pSA6, pSA8 and 
pSAlO (corresponding to fusions 2, 4 and 6 respectively) were not detected after induction of gene 
expression and Western blotting. This could, again, be due to degradation by cellular proteases. The 
PhoA assays of the PhoA domains of the hybrid proteins (Tables 3.3 and 3.4) have supported the 
expected topology for both Pen-2 and Aph-1. However, it can be argued that low PhoA activities 
were due to low or no expression of the corresponding phoA hybrids.
3.4.3 Conclusion
We describe previous cloning and expression of human ps-1, p s lAexon9, nicA and c99 and 
topological studies of PS-1, in E. coli. Additionally, in this chapter, successful cloning and 
expression of pen-2 and aph-1 and topological studies of the human proteins in E. coli were carried
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out. This represented a significant first step towards studying the human y-secretase complex in 
bacteria.
Chapter (4) Analysis o f the y-secretase components
CHAPTER (4)
ANALYSIS OF THE y-SECRETASE COMPONENTS
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4 ANALYSIS OF THE HUMAN y-SECRETASE COMPONENTS 
PRODUCED IN E. COLI
4.1 Introduction
As all four y-secretase components (Pen-2, Aph-1, PS-1 and NicA) and the y-secretase substrate 
(C99) were successfully expressed in E. coli, we decided to purify some of the proteins from E. coli 
cells. In this work, fast protein liquid chromatography (FPLC, Section 2.4.8, Materials and 
Methods) using Ni NTA was used to purify the recombinant human proteins from E. coli cells. 
Here we describe successfully purifying Pen-2 from the E. coli strain KU98. The availability of 
pure Pen-2 will be valuable for future assays aimed at further analysing the y-secretase complex 
and its activity. Pure Pen-2 can be used for interaction studies and the production of antibodies 
directed against Pen-2. Additionally, the pure protein can be analysed by mass spectrometry to 
answer such questions as the oligomeric state of Pen-2 and post-translational modifications. 
Furthermore, the Pen-2 can be used in experiments that involve mixing of purified y-secretase 
components to analyse the processing of C99 and Ap production, and to answer stoichiometric 
questions in complex assembly.
In this chapter we also describe the successful purification of C99 from the strain KU98, and 
subsequently analysing the pure protein by mass spectrometry. Additionally, pure C99 was used as 
a substrate for y-secretase assays performed in E. coli by either combining all four y-secretase 
components in the same strain, or by combining membranes of individual components. y-Secretase 
activity has been successfully reconstituted in eukaryotic cells but this did not rule out the presence 
of other endogenous proteins that could have been required for the activity. Therefore, bacteria 
provided a suitable system for the attempted reconstitution of y-secretase activity, to assess whether 
these four components are in fact the minimum components required.
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4.2 Purification studies o f  Pen-2
The pen-2 gene, cloned into pSAl contains an N-terminal His-tag. This allows the purification of 
Pen-2 by FPLC, using a Ni NTA chromatography column. Before the purification procedure could 
be performed, we needed to verify that Pen-2 was present in the bacterial membrane after 
expression. Hence, membranes containing the 6X histidine tagged Pen-2 were prepared.
4.2.1 Pen-2 is present in the membrane
A single colony of the strain KU98 containing the plasmid pSAl {pen-2 with an N-terminal his 
tag), was used to inoculate 200 ml of double NZA containing 200 pg/ml Amp and the culture was 
grown overnight at 28°C with shaking at 220 rpm. The overnight culture was then diluted 1/20 in 
the same medium (4 1) and grown until the O.D6 0 0  reached approximately 0.5. Expression of pen-2 
was induced by the addition of 100 pM IPTG and the culture was grown further at 20°C overnight, 
given that Pen-2 was found to be stable after overnight induction (Section 3.2.1.4, Chapter 3). 
Membranes were prepared as described in section 2.4.8.4, Materials and Methods. To solubilise the 
membrane proteins, they were re-suspended in lysis buffer containing 1% SDS and the mixture was 
stirred at room temperature for 2 hours. Here, a strong detergent was used rather than a mild 
detergent such as CHAPSO because Pen-2 is predicted to have no tertiary structure. In addition, the 
SDS was removed at a later stage to allow oligomerisation to occur. Samples from the different 
stages of the preparation and solubilisation of membranes were collected and approximately 30 pg 
(total protein, measured using the BCA kit from Sigma, Section 2.4.8.5, Materials and Methods) of 
each sample were loaded on Schaegger gels (Table 2.8, Materials and Methods) and subjected to 
Coomassie staining and Western blotting to monitor the efficiency of the procedure. Figure (4.1) 
shows that Pen-2 was present in the membrane fraction, and that solubilisation of the membrane 
proteins with SDS was effective. Western blotting confirmed that the majority of the Pen-2 in the 
bacterial membrane was solubilised with 1% SDS. However, the purification of Pen-2, solubilised
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from membranes was attempted a few times without success, as only a very small quantity of pure 
protein was collected after purification. Therefore it was suggested that Pen-2 was solubilised from 
whole cells to minimise loss o f the protein during membrane preparation, solubilisation and FPLC.
(A) Coomassie stained gel
Pen-2
(B) Western blot
Pen-2
Figure (4.1) Coomassie stained gel (A) and W estern blot (B) monitoring the preparation of
KU98 membranes containing Pen-2.
A 4 1 culture o f KU98 containing pSAl (pen-2 with an N-terminal his tag) was grown to log phase, when gene
expression was induced overnight by the addition o f 100 pM IPTG. Membranes were prepared as described in 
Materials and Methods and proteins were solubilised with 1% SDS for 2 hours at room temperature. Samples were 
removed after every stage of the procedure and loaded on Schaegger gels for Coomassie staining and Western blotting 
using a polyclonal antibody directed against the C-terminus o f Pen-2. Molecular weights are given in kDa.
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4.2.2 Purification of Pen-2 from E. coli by FPLC
Pen-2 was purified from whole cells by FPLC using Ni NTA, as described in section 2.4.8 in 
Materials and Methods. Solubilised proteins from whole cell extracts were loaded onto the NiNTA 
column with a flow rate of 0.5 ml/min. The detergent SDS which was used for the solubilisation of 
the membrane proteins was then exchanged for CHAPSO by loading approximately 5 column 
volumes of 0.2% CHAPSO onto the column. Washing with 10-100 mM imidazole removed 
contaminants but did not result in the loss of Pen-2. The protein was then eluted with 250 mM 
imidazole. All detergent exchange, washing and elution steps were performed with a flow rate of 2 
ml/min.
Samples were kept from the different stages of the purification procedure and the total protein 
concentration in each sample was measured using the BCA kit from Sigma. 30 pg protein of each 
sample were loaded on to a Schaegger gel for analysis by Coomassie staining (figure 4.3A) and 
Western blotting (figure 4.3B) using a polyclonal a-Pen-2 antibody. The gels show that more than 
50% of Pen-2 was solubilised from whole cell extracts, using SDS, and that the eluted protein was 
pure. To get a better picture of the bands in the pure protein fraction, pure protein was loaded on to 
a new Schaegger gel which was then subjected to Coomassie staining and Western blotting (Figure 
4.4). This figure showed that Pen-2 was pure and that it is purified in the form of SDS resistant 
dimers. The purification of Pen-2 typically resulted in a yield of about 1 mg protein per 4 litres of 
culture.
100
Chapter (4) Analysis o f the y-secretase components
*t »  »»
AD
Figure (4.2) Purification profile of Pen-2
4 1 o f KU98 cells producing Pen-2 were stirred at room temperature with 1% SDS to solubilise all the membrane
proteins. The mixture was centrifuged at 13,000 rpm for 10 minutes and the pellet was discarded. The supernatant 
containing the solubilised proteins was loaded onto a Ni NTA column. The column was washed with (A) 10 mM and 
20 mM imidazole (B) 50 mM and 100 mM imidazole to remove contaminants, and then pure Pen-2 was eluted (B) with 
250 mM imidazole.
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(A) Coomassie stained gel
Pen-2 dimer? 
Pen-2 monomer
(B) W estern Blot
Pen-2 dimer? 
Pen-2 monomer
Figure (4.3) Coomassie stained gel and W estern blot monitoring solubilisation and
purification of Pen-2.
Cells from a 4 1 culture were stirred at room temperature in 1% SDS for 2 hours. The supernatant was then loaded onto 
a Ni NTA column. The column was washed in increasing concentrations o f imidazole and then pure pen-2 was eluted 
with 250 mM imidazole. The samples were analysed by Schaegger gels and Western blotting using a polyclonal a-Pen- 
2 antibody. Molecular weights are given in kDa.
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4.2.3 Pen-2 forms SDS resistant oligomers
It was observed that after purification o f Pen-2 from whole cells, bands of different molecular 
weights were recognised by the polyclonal antibody directed against the C-terminus of Pen-2. 
Therefore, pure Pen-2 which was eluted at 250 mM imidazole was re-loaded onto a Schaegger gel. 
The gel was then stained with Coomassie blue and then subjected to Western blotting using a 
polyclonal a-Pen-2 antibody (Figure 4.4). This showed that Pen-2 is not only pure, but also that it 
forms oligomers. In addition to the band representing the Pen-2 monomer at 12 kDa, there is also a 
band at around 25 kDa which could represent a dimer. There were also bands of higher molecular 
weight detected, which could represent higher oligomers o f Pen-2 or aggregates which migrate as 
non-defined bands.
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Pen-2 Monomer
Figure (4.4) Gels monitoring the oligomerisation state of Pen-2.
Pure Pen-2 was loaded onto a Schaegger gel. In addition to the Pen-2 monomer, Coomassie staining and Western
blotting with a polyclonal a-Pen-2 antibody revealed the presence of high molecular weight bands, which could 
represent oligomers of Pen-2. Molecular weights are given in kDa.
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4.3 Purification o f C99
This was performed as described in Sandra Grau, PhD Thesis, 2004. Membranes of the strain 
KU98 expressing C99 were prepared as described in Materials and Methods and solubilisation of 
the membrane proteins with 1% SDS at room temperature was successful. The cleared supernatants 
were then loaded onto a Ni NTA column with a flow rate of 0.5 ml/min. The detergent (SDS) was 
exchanged for 0.025% DDM which was loaded onto the column. Washing with 20 mM imidazole 
removed contaminants but did not result in the loss o f C99. Pure C99 was then eluted with 500 mM 
imidazole. The purification of C99 typically yielded approximately 1.5 mg protein per 4 litres of 
culture.
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Figure (4.5) Coomassie stained schaegger gel monitoring the preparation of membranes and
solubilisation of C99 from bacteria.
The Coomassie gel showed that membrane preparation from KU98 cells producing C99 was successful and that
solubilisation worked well, as a larger amount of total protein was present in the supernatant fraction than that in the 
pellet fraction. Molecular weights are given in kDa.
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Figure (4.6) Purification of C99.
C99 membranes were solubilised with 1% SDS at room temperature for 2 hours. The cleared supernatant was loaded
onto a Ni NTA column with a flow rate o f 0.5 ml/min. The detergent (SDS) was exchanged for 0.025% DDM which 
was loaded onto the column. Washing with 20 mM imidazole removed contaminants but did not result in the loss o f  
C99. Pure C99 was then eluted with 500 mM imidazole. Samples from different stages o f the purification were loaded 
on Schaegger gels where they were Coomassie stained and subjected to Western blotting using a polyclonal a-C99 
antibody. Molecular weights are given in kDa.
105
Chapter (4) Analysis o f the y-secretase components
4.4 Mass Spectrometric Analysis o f C99
This work was published recently in the European Journal of Mass Spectrometry (Xiaodan Tian, 
2004).
The y-secretase cleaves APP at the C-terminus, producing Ap which forms the major component of 
AD plaques. Studying the C-terminal processing of APP by y-secretase will shed light on the 
mechanism by which it interacts with the y-secretase complex and therefore on the function of the 
y-secretase. Therefore, C99 produced in E. coli (Section 4.3, this chapter) was sent to Michael 
Przybylski’s laboratory at the University of Konstanz, Germany. Mass spectrometry (figure 4.7) 
was used to analyse the pure protein and it was found that the recombinant C99 we produced in 
bacteria had the precise expected molecular mass of 12 kDa, and that no post-translational 
modifications have occurred during its production in E. coli. Therefore, this was a good control for 
the material produced in this work.
Additionally, Circular Cichroism (figure 4.8) showed that the C99 polypeptide had an a-helical 
conformation whereas Ap peptides and cytosolic APP showed random coil conformations. These 
results illustrate that the recombinant protein has a conformation that is typical for transmembrane 
segments, and that an a-helical conformation of the substrate may be necessary for its interaction 
with y-secretase.
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12 3 3 6 .1676  
12 336
Detected mass (Da): 
Calculated mass (Da):
Figure (4.7) Mass spectrom etric analysis of C99
The FTICR measurements were performed with a Bruker (Bruker Daltonik, Bremen, Germany) Apex II FT-ICR mass
spectrometer equipped with a 7T superconducting magnet, a cylindrical infinity ICR analyser cell and an external 
Scout 100 fully automated X-Y target stage Maldi source with pulsed collision gas. A 100 mg/ml solution of2,5-di- 
dihydroxybenzoic acid (DHB)in acetonitrile:0.1% trifluoroacetic acid in water (2:1) was used as matrix for sample 
preparation. Calibration was performed with a standard peptide mixture with an m/z range of approximately 2.500.
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Figure (4.8) Circular Dichroism (CD) Spectrum of C99 in 50 mM Tris-HCl
The secondary structure o f the C99 peptide was studied by CD spectroscopy on a Jasco spectropolarimeter, model J-
720 (Jasco,Finland). The spectra were recorded at room temperature in quartz cells o f  0.1 cm path-length The 
concentration o f the C99 peptide was 250 pg/ml. Tris-HCl 50mM was used as solvent. The spectra were averages o f six 
scans between A.=190 and 260 nm. Results are expressed in terns o f  mean residue ellipticity in units o f deg cm2 dmol-1 
after subtraction o f buffer base-line
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Immmunisation of transgenic mouse models of AD with Ap42 has been recently effective to inhibit 
and disaggregate Ap fibrils, and to reduce AD-related neuropathology and memory impairments 
(Janus et al., 2000; Schenk et al., 1999). Xiaodan Tian and co-workers have identified the epitope 
recognised by the antibody as the N-terminal Ap(4-10) sequence. Therefore, this epitope opens new 
lead structures for the development of AD vaccines. Additionally, a monoclonal antibody (JmAb) 
directed against the cytosolic APP domain has been used in studies of APP biochemistry and 
metabolism (Bauer et al., 1991; Ganter et al., 1991; Jung et al., 1996). Xiaodan Tian and co- 
workers, report that the epitope recognised by the antibody is located at the C-terminal APP (740- 
747) sequence. This also will be an efficient tool in the development of new specific vaccines.
DAEFRHDSGYEVHHQKLVFR
M  epitope
LVMLKKKQ
Membrane
Cysteine-rich Acidic KPI
KKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
-"A/CD epitope
.EVKI/pAEFRHDSGYEVHHQIfl-VFFAEDVGSNK
&' 'a
AAA
Figure (4.9) Schematic representation of APP showing im portant regions of the molecule.
(a) Structure o f APP. The signal peptide is followed by the cysteine-rich region, an acidic region, the Kunitz-type
protease inhibitor (KPI) and 0X 2  domains that occur in some APP isoforms, a glycosylation site, a transmembrane 
region, and a cytoplasmic tail; (b) Sequence and structure o f  C99 and the position o f the Ap and APP intercellular 
cytosolic domain (AICD) epitopes; (c) The Ap region is shown which is a major component o f  Alzheimer’s disease 
plaques, and the a-, p- and y-secretase cleavage sites are indicated. Taken from Xiaodan Tian et al (2004).
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4,5 y-Secretase Assays
4.5.1 Measuring y-secretase activity produced by components combined in one 
bacterial strain
One approach to investigate y-secretase activity in E. coli involved combining the genes encoding 
y-secretase components in up to 3 plasmids and subsequently transforming the generated plasmids 
into the same E. coli strain. Therefore, TSS transformation was used to transform pSA14 (pen-2 
and aph-1), pSG34 (ps-1 and c-99) and pSG36 (nicA) into the strain KS272 (Sections 2.2.1 and 
2.3.1, Materials and Methods).
For expression, double NZA containing Amp (200 pg/ml), Cm (15 pg/ml) and Kan (100 pg/ml) 
was inoculated with a single colony of the strain KS272 containing pSA14, pSG34 and pSG36 and 
cells were grown to saturation overnight. The overnight culture was diluted 1/20 in the same 
medium and growth was maintained at 28°C until O.D6 0 0  reached approximately 0.5. At this point 
IPTG was added to a final concentration of 50 pM and aTet to a final concentration of 100 ng/ml. 
The culture was grown further at 20°C for 4 hours with shaking at 220 rpm. Membranes of the 
strain KS272 containing pSA14, pSG34 and pSG36 were prepared as described in section 2.4.8, 
Materials and Methods. The strain KS272 containing no plasmids was treated in the same manner 
to provide a negative control for the y-secretase assay.
To perform the y-secretase assay, KS272 membranes with or without y-secretase components (200 
pg/ml total protein) was added to 5 pg/ml pure C99 in lysis buffer (50 mM Tris-HCl pH 8.0 300 
mM NaCl) containing 1% CHAPSO. Reactions were mixed thoroughly and incubated at 37°C and 
samples were removed after 7 and 24 hours. The reaction was then stopped by quickly freezing the 
samples at -80°C. As a second negative control, cells were incubated in lysis buffer without the 
substrate, C99.
110
Chapter (4) Analysis of the y-secretase components 
4.5.1.1 Afi ELISA (Enzyme-Linked-Immun os or ben t-Ass ay)
To detect Ap produced as a result o f y-secretase activity, an ELISA kit from the Genetics Company 
(Catalogue number: TK40HS) was used. The kit provides highly sensitive and selective analysis of 
human AP40 and it can be used to detect Ap levels in the range of 25 to 500 pg/ml by comparison 
to a standard curve.
The antigen to be tested (Figure 4.10) is detected by monoclonal a-Ap antibodies at two different 
binding sites, forming a sandwich complex. The surface of the micro titer plate is coated with an 
antibody which selectively recognises the C-terminal end of the antigen. During the test procedure, 
a a-Ap antibody conjugate is incubated with the standard or sample and forms an antibody-Ap- 
antibody complex. This complex is indirectly linked to an enzyme, which catalyses the conversion 
of a substrate into a coloured product and the colour intensity can be measured by means of 
photometry. The measured extinction correlates directly with the concentration of Ap within the 
sample, and a quantification of the samples can be achieved by comparing the colour intensity to a 
standard curve using the concentrations of synthetic Api-40 plotted against their colour intensity.
The assay samples from section 4.5.1 were analysed by the Ap ELISA kit and the concentrations of 
Ap produced as a result of the y-secretase assay were calculated. Figure (4.11) shows that KS272 
containing the y-secretase components produced more Ap than the control KS272. In addition, it is 
clear that the optimum length of time for y-secretase activity to take place is between 7 and 24 
hours, as Ap levels begin to fall after 24 hours of incubation at 37°C.
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(1) Antibody coated microtitre plate
(2) Incubation of antibody conjugate 
and standards/samples
(3) Incubation of enzyme conjugate
(4) Incubation of enzyme substrate
Figure (4.10) Schematic representation of the Ap detection method produced as a result of y-
secretase activity, using an Ap ELISA kit
The presence o f Ap is detected by two antibodies, forming a sandwich complex. The complex is linked with an enzyme
which converts a substrate to a coloured product. The colour intensity o f  the product, which can be measured, directly 
corresponds to the concentration o f Ap present in the assay sample (Adapted from the manual for hAp40 ELISA kit 
from the Genetics Company, catalogue number: TK40HS).
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Figure (4.11) Ap production by E. coli
The strain KS272, and KS272 containing the plasmids pSA14 (pen-2 and aph-1), pSG34 (ps-1 and c-99) and pSG36
(nicA) was grown at 28°C until O .D ^  reached 0.5. IPTG (50 pM) and aTet (100 ng/ml) were added to induce 
expression o f the genes encoding the y-secretase components. The culture was grown further at 20°C for 4 hours with 
shaking at 220 rpm. Membranes were prepared and y-secretase assays were performed by mixing KS272 membranes 
with or without y-secretase components (200 pg/ml) with 5 pg/ml pure C99 in lysis buffer (50 mM Tris-HCl pH 8.0 
300 mM NaCl) containing 1% CHAPSO. Reactions were incubated at 37°C and samples were removed after 7 and 24 
hours. To detect Ap produced, the samples were analysed using an Ap ELISA kit from the Genetics Company. C: 
Control KS272 membranes, y: KS272 containing Pen-2, Aph-1, PS-1 and NicA.
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4.5.2 Measuring y-secretase activity produced by mixing of y-secretase components, 
individually expressed in KU98
The strain KU98 (Section 2.2.1, Materials and Methods) containing one of the plasmids pSAl 
(pen-2), pSA12 (aph-1), pMH13 (ps-lAexon9) and pMH42 (nicA) was grown overnight in double 
NZA medium containing 200 pg/ml Amp at 28°C. The overnight cultures were diluted 1/20 in the 
same medium and growth was maintained at 28°C until O.D6oo reached approximately 0.5. At this 
point IPTG was added to a final concentration of 100 pM and the cultures were grown further at 
20°C for 4 hours with shaking at 220 rpm. To check that the individual y-secretase components 
(Pen-2, Aph-1, PS-1 and NicA) were produced in KU98, whole cell extracts were loaded on 
Schaegger gels and Western blots were performed using a polyclonal antibody directed against 
Pen-2, Aph-1, PS-1 or NicA. All components except Aph-1 were detected on Western blots (Figure 
4.12). This was thought to be due to the fact that a newly obtained antibody was being used to 
detect Aph-1. Regardless, membranes of the strain KU98 containing one of pSAl, pSA12, pMH13 
and pMH42 were prepared as described in section 2.4.8, Materials and Methods.
To perform the y-secretase assay, KU98 membranes containing the different y-secretase 
components were mixed in equal concentrations (100, 300, 1000 and 3000 pg total protein). One 
half of the samples was mixed with lysis buffer (50 mM Tris-HCl pH 8.0 300 mM NaCl) 
containing 1% CHAPSO, and incubated overnight at 37°C to allow the complex components to 
interact and to allow cellular proteases time to degrade, so that the level of background cleavage of 
C99 can be reduced. The mixture of components was then added to 40 pg pure C99. The other half 
of the samples was treated in the same manner but was not pre-incubated before the addition of 
C99. Reactions were mixed thoroughly and incubated at 37°C and samples were removed after 6, 
24 and 30 hours. The reactions were then stopped by quickly freezing the samples at -80°C. As a 
negative control, samples were removed after incubation of the components with C99 for 0 hours.
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The samples were then analysed using an Ap40 ELISA kit from the Genetics Company, to test for 
the presence o f Ap40 and therefore y-secretase activity (Figures 4.1).
The Ap40 ELISA revealed that in general, pre-incubation o f the y-secretase components at 37°C 
before the addition of the substrate, C99, does not result in higher Ap levels produced, or in lower 
levels o f background. The results show that there is a general trend towards higher levels of Ap 
produced as a result o f the presence o f a higher concentration of y-secretase components as 
incubation of C99 with 3000 pg y-secretase components produced more Ap than samples 
containing lower concentrations o f components. Also, it seems that incubation for 24 hours is 
sufficient to allow y-secretase activity to take place.
Pen-2
NicA
Figure (4.12) W estern blots m onitoring expression of y-secretase components in KU98 for y-
secretase assays.
The strain KU98 containing either pSAl (pen-2), pMH13 (ps-lAexon9) or pMH42 (nicA) was grown at 37°C to log 
phase, when 1PTG (100 pM ) was added to induce gene expression. Cells were further grown at 20°C for 4 hours. 
Whole cell extracts were then loaded onto Schaegger gels and Western blots were performed using polyclonal 
antibodies directed against the individual components.
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Figure (4.13) Ap production in E. coli
K.U98 membranes containing Pen-2, Aph-1, PS-1 and NicA separately, were mixed in equal concentrations (100, 300,
1000 and 3000 pg total protein). The mixture o f  membranes was added to 40 pg pure C99 in lysis buffer (50 mM Tris- 
HCl pH 8.0 300 mM NaCl) containing 1% CHAPSO, and incubated at 37°C to allow y-secretase activity to take place. 
Samples were removed after 6, 24 and 30 hours and the reactions were stopped by quickly freezing the samples at - 
80°C. The same was repeated but membranes were incubated at 37°C for 24 hours before C99 was added. As a negative 
control, samples were also removed 0 hours after the addition o f  C99. In the figure: 1= with pre-incubation, NI= no pre­
incubation, 100/300/1000/3000= amount o f  membranes used in pg total protein, 0/6/24/30= number of hours assay at 
which sample was removed.
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4.6 Discussion
4.6.1 Recombinant Pen-2 and C99 can be purified from E. coli cells
Results in this chapter indicate that Pen-2 produced in KU98 and processed by FPLC was pure, as 
shown by a Coomassie stained gel and confirmed by Western blotting (Figures 4.3 and 4.4). In 
addition to the 12 kDa band which represents Pen-2, other bands with higher molecular weights 
were observed. These bands were also recognised by the polyclonal a-Pen-2 antibody which 
confirms that they also represent Pen-2 but at higher oligomeric states. In future, it would be 
interesting to investigate those SDS resistant oligomers of Pen-2, perhaps by mass spectrometry. 
This method can also be used to confirm that the correct protein was produced and purified in E. 
coli, and to verily its expected molecular weight. Additionally, pure Pen-2 could be used for the 
production of polyclonal antibodies.
The plasmid pSA16 containing pen-2 with an N-terminal his tag and tag-less aph-1, could provide 
the basis for a co-purification experiment. The plasmid can be transformed into the strain KU98 
and expression of both pen-2 and aph-1 can be induced by the addition of IPTG and allowing the 
induction to take place for 4 hours, as Aph-1 was found to be unstable overnight. Following that, 
membranes can be prepared and the membrane proteins solubilised. However, Aph-1 has 6 
transmembrane segments and probably considerable tertiary structure and therefore an alternative 
to solubilisation with SDS can be considered. Pen-2 can be produced with an N-terminal his tag 
and therefore purification with Ni NTA will be appropriate. The Elution fractions can then be tested 
for the presence of Aphl, which would indicate co-purification with Pen-2 and therefore a direct 
interaction between the two y-secretase components.
Additionally, we describe the successful purification of the substrate C99 from E. coli cells. 
Moreover, Western blotting (figure 4.6) shows that C99 was purified as a monomer, but that higher
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oligomers were also present, which seems to be common for this protein (Sandra Grau, PhD Thesis, 
2004).
Pure C99 was then studied by mass spectrometry which confirmed that the genuine human 
recombinant protein was produced and purified in bacteria, and it verified that C99 had the 
expected molecular weight. Additionally, Tian and co-workers have identified crucial epitopes of 
the APP molecule that are recognised by specific antibodies. Knowledge of these epitopes could 
have great potential, as it may provide the basis for the design of artificial molecules for 
vaccination.
4.6.2 Ap detected in the presence of y-secretase components and C99, in initial assays
In the first y-secretase assay (section 4.5.1), all y-secretase components were combined by 
transforming the plasmids pSA14 (pen-2 and aph-1), pSG34 (ps-1 and c-99) and pSG36 (nicA) into 
the strain KS272. Expression of the recombinant human proteins was induced for 4 hours but with 
the exception of Pen-2, they were barely detectable on Western blots (data not shown). This could 
have been due to the fact that the presence of 3 plasmids in one strain was stressful for the bacterial 
cells and therefore expression was not properly induced. Additionally, one suggestion could be that 
expression of the four y-secretase components could be optimised by testing varied concentrations 
of the inducers IPTG and aTet. However, it is possible that all y-secretase components were in fact 
expressed in KS272, but that expression levels were so low that Western blotting was not sensitive 
enough to detect their presence. Therefore, the y-secretase assay was carried out as described in 
section 4.5.1, and samples were analysed using the Ap ELISA. The results showed that KS272 
cells, producing y-secretase components, produced more AP detected by ELISA, than control cells 
containing no components. They also showed that after 24 hours Ap levels begin to fall therefore, 
the experiment needs to be repeated and samples removed between the time points of 7 and 24 
hours to determine the optimum length of time for the assay.
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Additionally, the Ap ELISA revealed that lack of added purified C99 to cells containing the y- 
secretase components resulted in no Ap detected. This is surprising because KS272 contained the 
plasmid pSG34 which contains c99. However it is possible that Ap is produced, but in small 
amounts that are then degraded by cellular proteases such as DegP (Clausen et al., 2002; Krojer et 
al., 2002; Spiess et al., 1999). Perhaps altering the incubation time for this assay could help with 
this problem.
In the second assay, each component was expressed individually in KU98 and then the membranes 
containing the individual components were combined. All components could be detected via 
Western blotting except Aph-1. This was thought to be due to the fact that a new Aph-1 antibody 
was obtained and its use was not yet optimised. However on some Western blots (data not shown), 
Aph-1 could be detected as a very faint band. Therefore, it was thought that perhaps the protein was 
in fact produced but in very low amounts that could not be detected using Western blotting, y- 
secretase assays followed by Ap ELISAs in this case showed that there was not much difference 
between test and control samples, although test samples still produced higher levels of Ap. 
Incubation for 24 hours again was sufficient for Ap production and higher concentrations of y- 
secretase components in the assay samples resulted in higher levels of Ap detected. However, pre­
incubation of the membranes containing the y-secretase components at 37°C for 24 hours did not 
result in higher levels of Ap. Also, excess concentrations (40 pg) of the substrate C99 were used in 
the assays, which could have resulted in higher background levels of Ap detected as C99 is also 
degraded by cellular proteases still remaining even after pre-incubation for 24 hours.
However, both assays produced result values in the region which can be detected by the ELISA kit 
but they were still in the lower range o f the scale and therefore may not be very accurate. It was 
also observed the second assay carried out by mixing of y-secretase components individually 
expressed in the strain KU98, produced higher levels of background. This was thought to be due to
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the higher concentration of total membrane proteins used in this assay when compared to the first 
assay. And although there is no endogenous y-secretase activity in E. coli, cellular proteases could 
be responsible for cleaving C99 and producing Ap.
Akiyama and Ito (Akiyama and Ito, 2003) have created a new experimental technique for studying 
the action of proteases. They studied E. coli FtsH which is a membrane bound and ATP-dependent 
protease which brings about degradation of numerous membrane proteins. Among the ATP- 
dependent proteases (e.g. Lon) of E. coli, FtsH is unique in that it is a transmembrane protein and 
that its substrates include integral membrane proteins e.g. the SecY subunit of protein translocase 
(Akiyama et al., 1998). The membrane localisation of FtsH is essential for its role as a protease for 
membrane proteins(Akiyama and Ito, 2000). Furthermore, the proteolytic activity of FtsH is 
stimulated by the proton motive force (PMF) across the membrane (Akiyama, 2002).
In vitro reaction systems using detergent solubilised enzyme and substrates were unsuitable for 
characterising the activities of FtsH to degrade membrane integrated substrates, because such 
important features as the dislocation and the PMF stimulation could not be addressed. It was also 
difficult to prepare membrane vesicles carrying both FtsH and its degradation substrate. Therefore, 
Akiyama and co-workers prepared separate membrane vesicles, one carrying the enzyme and the 
other carrying a substrate. These membrane vesicles could then be fused to enable the enzyme- 
substrate interaction, by using PEG3350 to cause an ATP degradation of the substrate (Akiyama 
and Ito, 2003). Similarly, it was thought that this reaction system could adapted to demonstrate y- 
secretase activity. Membranes of a suitable E. coli strain containing one of the plasmids containing 
pen-2 and aph-1 (pSA14, pSA16, pSA18) can be prepared, in addition to those containing the other 
y-secretase components (e.g. pSG34 containing pslAexon9 and c99, and pSG36 containing nicA). 
The membranes could then be fused following the protocol outlined by Akiyama and co-workers,
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followed by the addition of the substrate C99 to perform the assay and test for occurrence of y- 
secretase activity.
4.6.3 Conclusion
Pen-2 and the y-secretase substrate, C99, have been successfully purified from bacteria which will 
allow them to be utilised in various assays investigating y-secretase activity, and enable further 
analysis of their structure, function and interaction with other y-secretase components. 
Additionally, initial assays involving the four y-secretase components in E. coli demonstrate a lot of 
potential for the system; however additional work needs to be carried out to optimise the assay 
conditions and to investigate the reaction further.
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5 THE E. COLI TWO-HYBRID SYSTEM FOR THE DETECTION 
OF HUMAN PROTEIN INTERACTIONS
5.1 Introduction
To aid the study of the function of each of the components of the y-secretase complex (Pen-2, Aph- 
1, PS-1 and NicA) and their roles in bringing about y-secretase activity, their interactions with each 
other and with the substrate APP needed to be analysed. As already mentioned in the introduction 
(Chapter 1), E. coli two-hybrid systems seem more suitable than yeast two-hybrid systems for such 
a study. The smaller genome complexity of E. coli and greater evolutionary distance from higher 
eukaryotes mean that E. coli two-hybrid systems should not generate as many false positives and 
negatives due to interactions between endogenous proteins and eukaryotic bait and prey. 
Additonally, E. coli grows much faster than yeast and can be transformed with higher efficiency, 
allowing better coverage in library-based screens. (Hu et al., 2000).
It has been shown that interaction between any two proteins can activate transcription in E. coli 
provided one of the interacting proteins is bound to the DNA via a DNA binding domain (DBD) for 
example the lambda repressor Xcl, and the other interacting protein is bound to an RNA polymerase 
(RNAP) subunit for example the co-subunit (Dove et al., 1997). Here, we construct plasmids 
containing some of the y-secretase components (aph-1 and nicA), fused to either Ac/ or the co­
subunit of RNAP according to the protocol outlined by Dove and co-workers, Harvard Medical 
School, Boston (Dove and Hochschild, 1998). Subsequently, the plasmids containing the 
investigated proteins, along with the reporter plasmid pRW50/417 containing the lacZ gene 
(Section 2.3.1, Materials and Methods) were transformed into an E. coli strain. When the two 
investigated proteins interact, transcription of the lacZ gene is activated producing a phenotype 
which can be measured by performing p-galactosidase assays.
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5.1.1 The interaction between PS-1 and the y-secretase substrate, C99
There is strong evidence to show that presenilins are able to interact directly with APP. Complex 
formation between APP and PS-1 and -2 has been demonstrated by co-immunoprecipitation of both 
proteins (Waragai et al., 1997; Weidemann et al., 1997; Xia et al., 1997). Consequently, work 
recently done in this lab has shown that PS-1 and C99 interact in an E. coli two-hybrid system 
(Hamasch et al., 2004). The plasmid pCB6 containing PS-1 fused to the X repressor and C99 fused 
to the co-subunit of RNAP was constructed (Section 2.3.1, Materials and Methods). A p- 
galactosidase assay in the presence of pCB6, in addition to the reporter plasmid pRW50/417 
(Section 2.3.1, Materials and Methods) produced a high signal. In addition, Western blots with 
antibodies against PS-1 and C99 showed that the two proteins are stably co-expressed (Figure 5.1).
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(A ) P-galactosidase assays
units-
XcI-(o Acl-Gal^ XcI-PS-1
to-Gall l p C99-W
(B) Expression o f  gene fusions
< —  A.cI-PS-1
<«—  C99-(o
Figure (5.1) The interaction between PS-1 and C99 in an E. coli two-hybrid system
(A)The P-galactosidase assays indicate a low level response in the presence o f  the empty vector controls. The yeast
GaL» and Gall l p proteins, serving as a positive control, lead to a positive signal in the p-galactosidase assays. The 
signal from the ?icl-PS-l/C99-(o construct is even higher, p-galactosidase assays were performed in whole E. coli 
cells under standard conditions. (B)W estem blot with antibodies against C99 and PS-1 showing stable expression 
o f full length constructs (Pictures from Christian Behrend, Diplom thesis, 2002)
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5.1.2 Screening a cDNA library for interaction partners of PS-1 and PS-lAexon9
Additionally, before the components o f the y-secretase complex were known, it was interesting to 
identify proteins that interacted with PS-1, as it was postulated to be the y-secretase or the active 
site of the y-secretase complex. It was thought that proteins that interact with PS-1, may be 
involved in y-secretase complex assembly or export of PS-1 to the relevant cellular compartment or 
alternatively, they were substrates of PS-1. Our strategy for identification of interaction partners of 
PS-1 was the use of the E. coli two-hybrid system composed of PS-1 fused to the X repressor, and a 
human foetal brain cDNA library fused to the co-subunit of RNAP (Figure 5.2). We also screened 
for proteins that interacted with the gain of function PS-1 mutant, lacking exon 9 (PS-lAexon9), as 
it is linked to familial Alzheimer’s disease (FAD). The plasmids containing the PS-1 and PS- 
1 Aexon9 fusion genes were constructed by Christian Behrends (Behrends, 2002).
The reporter cassette used in this screen has been incorporated on an F’ episome and contains the 
Amp and the p-galactosidase gene. The activatable promoter in the reporter gene casette is a 
modified lac promoter that contains a single X operator (Or2) centred at position -62, replacing the 
CRP-binding site originally associated with the lac promoter. To enhance the reporter gene 
expression, the Shine-Dalgamo translational signal is also included upstream of the reporter genes.
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Figure (5.2) Schematic representation of the interaction between proteins encoded by the
cDNA library and PS-1 or PS-lAexon9.
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5.2 Detection o f two-hybrid, interactions between y-secretase components
5.2.1 Construction of the plasmids pSA19, pSA20 and pSA21 containing the gene
fusions a)-aph-l, Xcl-aph-l and co-nicA, respectively
The aph-1 gene was amplified from the plasmid pCDNA (zeo) Aphla251 (Section 2.3.1, Materials 
and Methods) using the oligonucleotides “cI-Aphl/Aor/” and “cI-AphlIBgllF  to allow fusion to Xcl 
and the oligonucleotides “w-Aphl/TVo/T” and “w-Aphl/SW/” (Section 2.3.2, Materials and Methods) 
were used to amplify the aph-1 gene to allow fusion to the oo-subunit of RNAP. PCR products with 
the appropriate flanking restriction sites were produced, which were then ligated into the vectors 
pCBl containing Xcl and pBRco containing the co-subunit of RNAP (Figure 5.3). The resulting 
plasmids, pSA19 (co-aph-1) and pSA20 (Acl-aph-l) were controlled by digestion with suitable 
restriction enzymes and were analysed by agarose gel electrophoresis.
Similarly, the nicA gene was amplified from the plasmid pMH42 (Section 2.3.1, Materials and 
Methods) using the Oligonucleotide “NicA-w/Afafe/” as a forward oligonucleotide and “NicA- 
w/NotF as a reverse oligonucleotide (Section 2.3.2, Materials and Methods). PCR products with 
the appropriate flanking restriction sites were produced, which were then ligated into the vector 
pBRco containing the co-subunit of RNAP. The resulting plasmid, pSA21, was controlled by 
digestion with suitable restriction enzymes and analysed by agarose gel electrophoresis. Figure 
(5.3) can be used for reference.
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Figure (5.3) Schematic representation of the construction of pSA19 and pSA20 containing co-
aph-1 and Xcl-aph-1 respectively
The aph-1 gene was amplified from the plasmid pCDNA (zeo) Aphla251. For the construction o f pSA19, the aph-1
PCR product with flanking restriction sites was ligated into pBRco via Sail and Not I, and for the construction o f pSA20, 
the aph-1 PCR product was ligated into pCBl via Bglll and Notl, replacing the ps-1 sequence.
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5.2.2 p-galactosidase assays to monitor protein-protein interactions
Simon Tunster (Tunster, 2004) performed P-galactosidase assays using the plasmids pSA19, 
pSA20 and pSA21 containing co-aph-1, lcl-aph-l and co-nicA respectively, to analyse protein- 
protein interactions between various y-secretase components and the y-secretase substrate, C99. 
Genes encoding the proteins investigated were fused to either the co subunit gene or the X repressor 
gene (This work and Hamasch et al., 2004). The resulting plasmids were then transformed into the 
strain MC4100 along with the reporter plasmid pRW50/417, and p-galactosidase assays were 
carried out as described in Materials and Methods (Section 2.4.7). High levels of p-galactosidase 
activity indicated a high level o f transcription o f the LacZ gene and therefore strong interactions 
between the investigated proteins. The results o f the p-galactosidase assay indicated that PS-1 
interacts with C99 and NicA as there was an increase in p-galactosidase activity, when compared to 
the control. It was also shown that Aph-1 does not interact directly with the y-secretase substrate, 
C99, but that it interacts with both PS-1 and NicA. Table (5.1) below outlines the constructs used to 
perform this assay. As a negative control (red), just the reporter plasmid pRW50/417 was 
transformed into MC4100 and the assay carried out as described. The PS-1 interaction with C99 
was used as a positive control (blue).
Interacting protein 1 Interacting protein 2 p-galactosidase activity 
(units)
LacZ gene (pRW50/417) - <0.1
XeI-PS-1 (pCBl) co-Aph-1 (pSA19) 1.3
XeI-PS-1 (pCBl) C99-co (pCB2) 0.9
Ael-Aph-1 (pSA20) C99-co (pCB2) <0.1
tel-PS-l (pCBl) co-NicA (pSA21) 1.15
Xcl-Aph-1 (pSA20) co-NicA (pSA21) 1.0
Table (5.1) Interaction between y-secretase components measured by p-galactosidase activity
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5,3 Screening a human foetal brain cDNA library for interaction partners of PS-1 
and PS-lAexon9 using the E, coli two-hvbrid system
5.3.1 Isolation and amplification o f the cDNA library supplied
The cDNA library was cloned so that it is fused to the a-subunit of RNAP in the plasmid pTRG 
XR (Tet resistant) from Stratagene. In order to be able to use library DNA repetitively, the cDNA 
library needed to be amplified. XL 1-blue M RF’ Kan cells (Section 2.2.1, Materials and Methods) 
containing the cDNA library inserts were grown at 28°C, since from previous experience we 
established that membrane proteins demonstrated improved stability when cells producing them 
were grown at lower temperatures. Additionally, in order to screen for non-membrane proteins, 
cells were grown at 37°C as well.
The isolation and amplification procedure of the cDNA library is described in figure (5.4). 1 ml 
XLl-blue MRF’ Kan cells were thawed, and 150 pi were mixed with 20 ml SOB liquid medium 
and 100 pi were plated on each of 200 NZA agar plates containing 15 pg/ml Tet. 190 plates were 
incubated at 28°C whereas 10 plates were incubated at 37°C overnight. A lawn of cells grew on the 
plates and cells were harvested by scratching them off the plates. Subsequently, DNA was isolated 
using the QIAquick midipreparation kit from Qiagen. This yielded 2 ml of cDNA library inserts 
from 28 °C and 1 ml from 37°C.
Additionally, 1 1 of LB liquid medium was inoculated with 100 pi library cells and incubated O/N 
at 28°C and the same was repeated and the culture was incubation at 37°C. 300 ml of the overnight 
culture grown at 28°C, and 300 ml of the culture grown at 37°C were used to isolate DNA via 
midipreparation. This yielded 1 ml cDNA library from each temperature. The rest of the 11 LB
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culture from each temperature (700 ml) was frozen at -20°C. Two minipreparations were performed 
with the remaining 650 pi of thawed XL1 MRP4 Kan cDNA library cells. This yielded 0.2 ml of 
unamplified cDNA library.
1 ml XL1 Blue MRF’ Kan Cells
200 (jJ. for liquid media 150 pi for agar plates Isolation of DNA
Mixed with 21 SOB
1 137*C O/N 
/
700 ml -20°C
1 128°C O/N
300 ml
700 ml -20°C
Mixed with 20 ml SOB 
100 pi
10 NZA agar 
plates at37°C
|  O/N 
Lawn
0.2 ml unamplified 
cDNA library
100 pi
190 NZA agar 
plates at28°C
O/N |
Lawn
300 ml Isolation of DNA
Isolation of DNA
1 ml cDNA library 
from 37*C culture
1 ml cD N A  library  
hu m  37*C plates
1 ml cDNA library 
hu m  28"C plates
1 ml cJ)NA library  
from 28°C culture
Figure (5.4) Schematic representation of the procedure performed to isolate the cDNA
library.
5.3.2 Analysis of the cDNA library isolated
To determine the concentration o f cDNA library DNA isolated, 2 pi of each sample of amplified 
DNA and 5 pi of the unamplified library, were loaded on 1% agarose gel (Figure 5.5A). The gel 
shows the quantities of cDNA library DNA isolated. Abundant DNA was isolated as compared 
with that of the unamplified cDNA library, and it was sufficient for use in the cDNA library 
screening experiments.
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Additionally, as we had no experience in using this library from Stratagene, it was necessary to rule 
out the possibility that all the cDNA library inserts were identical. Hence, the cDNA library DNA 
isolated was transformed into MC4100. Four o f the transformants obtained were used for the 
minipreparation o f plasmid DNA. 10 p.1 aliquots o f each preparation were analysed by agarose gel 
electrophoresis to show different migrations due to the different cDNA library inserts (Figure 
5.5B).
1 2 3 4 5
8.45
7.24
6.39
4.82
3.67
i-
(B)
Figure (5.5) Agarose gels analysing the cDNA library isolated
The cDNA library was amplified from XL 1-blue MRF’ Kan cells (Stratagene) by growing the cells on agar plates and
in liquid cultures o f  SOB medium, at 28°C and 37°C. The DNA was then isolated using mini- or midi-preparation kits 
from Qiagen, and loaded onto 1% agarose gels. (A) The lambda DNA-BstElI digest from NEB was used as a ladder. 
Lane 1: Unamplified cDNA library (10 pi). Lanes 2 & 3: DNA from 1 1 cultures at 37°C and 28°C respectively. Lanes 4 
& 5: DNA from agar plates at 37°C and 28°C respectively. (B) DNA isolated from XL1 MRF’ kan cells was 
transformed into the strain MC4100 and isolated using a midipreparation kit (Qiagen). Lambda DNA-BstEIl from NEB 
was used as a DNA ladder and Lanes 1-4 are the different cDNA library inserts showing different migrations on 
agarose. Sizes o f DNA fragments are given in kilo basepair (kb).
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5.3.3 Determining the type of agar plates to be used in the screening procedure
Before screening the cDNA library for interaction partners of PS-1 and PS-lAexon9, it was 
necessary to decide what type of agar plates were to be used for the screening procedure. The 
plasmids pACLGF2  containing Xcl fused to Gal4 (Cm resistant) and pB R aG alllp containing the 
the a  subunit of RNAP fused to Gall l p (Tet resistant), were transformed into the strain CB4 
already containing the reporter lacZ gene(Kan resistant). This was used as a positive control as the 
proteins Gal4 and Gall l p are known to interact in an E. coli two-hybrid system, as mentioned in 
Chapter (1) of this thesis. On the other hand, The plasmids pCBl containing Xcl fused to ps-1 (Cm 
resistant) and the plasmid pBRstara containing the a  subunit of RNAP (Tet resistant), in the strain 
MC4100 were used as a negative control. This was because these cells will contain the bait hybrid 
and an in-complete prey hybrid.
All plasmids used in the screening procedure were Cm, Tet or Kan resistant. However, protein- 
protein interactions cause increased transcription of the bla gene on the reporter plasmid, conferring 
Amp resistance, resulting in cells containing interacting proteins growing on Amp plates. 
Therefore, it was decided that the best plates for use in the screening procedure were NZA agar 
plates containing Amp, Cm and Tet to ensure only transformants that grow on Amp are analysed 
further, MacConkey lactose plates containing Cm, Tet and Kan for visualising protein-protein 
interactions as a colour change, and NZA agar plates containing Cm, Tet and Kan to ensure the 
MC4100 cells contained all the desired plasmids. It was found that the positive control grew on 
Amp and caused the appearance of red colonies on MacConkey agar plates, and the negative 
control did not grow on Amp and caused the appearance of white colonies on McConkey agar 
plates.
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5.3.4 The screening procedure
53.4.1 Isolation o f candidate interaction partners ofPS-lwt and PS-lAexon9
This procedure is outlined in figure (5.6).The plasmid pTRG XR (Section 2.3.1, Materials and 
Methods) containing the cDNA library fused to the a-subunit of RNAP was transformed using the 
high yield method of electrotransformation (Section 2.3.8.2, Materials and Methods) into the 
electrocompetent cells CB4 containing pCBl (te l-p s-l)  and CB4 containing pCB13 (Acl-ps- 
lAexon9). Following a 1 hour period o f phenotypic expression in 1 ml NZA at 28°C and 37°C, the 
E. coli cells were plated out (100 pi and 900 pi) on NZA Amp plates (300, 500, 750 and 1000 
pg/ml final concentration). Different concentrations of Amp were used in order to enable us to 
determine what Amp concentration is best for minimising background growth.
After the overnight incubation, the transformation plates were inspected and a lawn was observed 
on all the plates. Therefore, all the plates were replicated on NZA agar plates containing the 
appropriate Amp concentration and incubated overnight at the appropriate temperature. 
Subsequently, single colonies were observed on some of the plates. A few colonies were picked 
and patched on NZA plates containing Amp, NZA plates containing Amp, Cm and Tet, and 
MacConkey plates containing Cm, Tet and Kan. The plates were then incubated overnight at the 
appropriate temperatures. No positive candidates were obtained from these plates.
A lawn was observed on some of the replica plates therefore, those plates were replicated again and 
some cells were patched on the same plates as before. Also, single colonies obtained from the 
replica plates were patched as before. Cells that grew on Amp and had a red phenotype on 
MacConkey lactose plates were considered to be positive candidates. The purified single colonies 
were then purified and re-tested 4 times on NZA and MacConkey plates containing Cm, Tet and
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Kan to verify that they were pure and homogenous. If the patches were heterogenous, then the 
single colonies were streaked out again and patched, until it could be verified that they were pure, 
otherwise they were not investigated further. NZA medium with the appropriate antibiotics was 
inoculated with a single colony of E. coli containing a positive candidate for use in the preparation 
of DMSO stocks for storage of the strains and mini preparations of plasmid DNA.
5.3.4.2 Validation o f detected protein-protein interactions
91 positive candidates were isolated, but in order to exclude, for example, promoter-up mutations 
in the reporter gene or any other mutation that could cause a false positive phenotype, plasmid 
DNA of the candidates was re-tranformed into cells that were not subjected to selection and 
screening media. Therefore, candidates were transformed into the strain CB4 containing pCBl 
(Acl-ps-l) and CB4 containing pCB13 (AcI-ps-lAexon9). The single colonies from the 
transformantion plates were picked and patched as before, and cells that contain a bait hybrid and 
an incomplete prey hybrid (CB4 with pCBl and pBRa or CB4 with pCB13 and pBRa) were used 
as negative controls. 30 candidates were found to be false positives, and those that could 
reproducibly produce a positive phenotype on plates were analysed further.
Subsequently, the target plasmids containing the remaining 61 positive candidates were 
transformed into CB4 cells containing pACZcI3.2. The plasmid pACA,cI3.2 is an incomplete bait 
hybrid because it does not encode the bait protein (PS-1 or PS-lAexon9). 11 transformants 
produced a positive phenotype on plates and so they were regarded as false positives. This could 
occur when the positive candidate itself contains a DNA binding domain. In this case, the bait 
hybrid fused to Xcl is not required to bind to the DNA. Instead, transcription of the LacZ is 
activated as a result of the prey hybrid itself binding to DNA, resulting in a false positive 
phenotype.
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Single colonies of the cells containing the remaining positive target plasmids were transformed into 
MC4100 and incoculated overnight for DMSO stocks and minipreparations of plasmid DNA. 
Plasmid DNA was then sequenced according to the protocol in section 2.3.10, Materials and 
Methods. Simultaneously, they were re-transformed into the strain CB4 containing pCBl and CB4 
containing pCB 13 and patched to verify that they were positive and homogenous.
5.3.4.3 Further analysis o f verified positives
50 verified positives were obtained which grew on Amp and produced a light to intensive red 
colour on McConkey lactose plates. To identify the protein encoded by the target DNA, the 
nucleotide sequence of the target DNA was determined and the sequence was then compared to the 
human genome sequence in the Blast database, to identify related proteins and the chromosomal 
locations of the candidates were obtained (Table 5.2). One of the positive candidates (not shown) 
had no sequence similarities in -the databases. This was surprising because at the time of the screen, 
the whole human genome sequence was known. An explanation for this could be that when the 
human cDNA library was constructed, it was contaminated with sequences from another organism 
whose genome had not been sequenced at the time.
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Figure (5.6) Schematic representation of the procedure used for screening a human cDNA 
library for interaction partners of PS-1 and PS-lAexon9 using the K  coli two-hybrid system
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Mitochondrion
genome
- 5 0
Beta 5 tubulin 
(TBB5)
19pl3.3 4 2
Ribosomal protein 
L23a (RPL23A)
17ql 1 1 0
Ets-variant gene 5 
(ETV5)
3q28
7q33-q36
0 2
Interferon gamma- 
inducible protein 16 
(IFI16)
lq22 4 0
GTP-binding protein, 
RAS oncogene family 
(RAB3A)
19pl3.2 1 0
Lantibiotic synthase 
component C-like 1 
(LANCL1)
2q33-q35 0 2
KIAA0614 12q24.21
14q24.3
1
Ring finger protein 
27 (RNF27)
10q24.3 1 0
Lamin A/C (LMNA) Iq21.2-q21.3 0 1
New gene following 
KIAA1337
lp36.22 4 0
HS1 protein 22ql2-qter 1 0
Novel gene lp35.1-36.23 1 0
Novel gene 7q33-q36 0 15
Novel gene 12q24.1 0 1
Novel gene 14q24.3 1 0
Novel gene Xp21.1-21.3 1 0
Novel gene Xp22 0 1
Table (5.2) Interaction partners of PS-1 and 1PS-lAexon9 as determined by the E. coli two-
hybrid screening procedure.
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5.4 Discussion
5.4.1 Two-hybrid interactions are detected between y-secretase components, and the 
substrate C99
The E. coli two-hybrid system was successfully utilised to identify a number of interactions that 
occur between components of the y-secretase complex. It is now widely accepted that PS-1 
comprises the active site of the y-secretase complex, harbouring the two active site aspartates in 
transmembrane domains 6 and 7, in the N- and C-terminal fragments of PS-1, possibly generated 
by autoproteolysis (Prokop et al., 2005). Therefore, an interaction between PS-1 and C99 was 
expected and it was shown using the E. coli two-hybrid system. However, it was not clear whether 
other y-secretase components interacted with each other or with C99 prior to the y-secretase 
complex assembly. It has been suggested that other components are required for assembly, 
stabilisation and maturation of the complex and that NicA may be involved in the recognition of 
substrates (Steiner, 2004).
Results in this chapter indicated that Aph-1 does not directly interact with C99, as was shown by 
the p-galactosidase assays performed. However, interactions were observed between Aph-1 and 
PS-1. This was thought to be due to the fact that this interaction was necessary for forming the 
“scaffold” for the y-secretase complex (De Strooper and Woodgett, 2003). The E. coli two hybrid 
system in this work suggested that PS-1 and NicA interact, and therefore it is probably also 
necessary for Aph-1 to interact with NicA, so that the PS-1/NicA intermediate can be stabilised. 
Additionally, Shirotani and co-workers (Shirotani et al., 2004) suggested that there is a stable 
interaction between NicA and Aph-1, independent of PS-1 and Pen-2. Furthermore, it was 
suggested that Pen-2 is necessary for the stabilisation of the PS NTF and CTF (Prokop et al. 2005), 
therefore it would be interesting to use the E. coli two hybrid system to analyse that possible 
interaction.
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Additionally, regardless of the lack o f evidence for successful expression of co-aph-1, Xcl-aph-l 
and co-nicA from the plasmids pSA19, pSA20 and pSA21, respectively, P-galactosidase assays 
were still carried out. The results of the assay not only indicate that the y-secretase components 
interact but also that they must be stably expressed. Perhaps they were expressed in very small 
amounts that could not be detected well using Western blotting but that these amounts were 
sufficient for a two-hybrid interaction.
5.4.2 Screening the cDNA library using the E. coli two-hybrid system, identified 
candidate interaction partners o f PS-1 and PS-lAexon9
The cDNA two-hybrid screen yielded 50 “hits” from the screening procedure. After sequencing and 
identification (where possible) of the cDNA library inserts, 18 different potential interaction 
partners of PS-1 and PS-lAexon9 were obtained.
Looking at table (5.2) in the Results section, it is shown that some of the candidates isolated by the 
screening procedure interact with either PS-1 or PS-lAexon9. It would be interesting in the future 
to re-transform the isolated cDNA library insert into a reporter strain with the other presenilin to 
determine whether the interaction observed in the screening is specific to PS-1 or PS-lAexon9. For 
example, Ribosomal protein (L23a) was isolated as an interaction partner of PS1, but not 
PSlAexon9, so if it was re-transformed into a strain containing the reporter plasmid and pCB13 
(A,cI-PSlAexon9) then the importance o f exon 9 for the interaction can be determined.
A few interesting genes were isolated as interaction partners of at least one of the presenilins. For 
example, RAB3A, a GTP-binding protein belonging to the RAS oncogene family was isolated as 
an interaction partner of PS1. This is interesting because previously Dumanchin et al. (Dumanchin
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et al., 1999) found that RAB11 interacts with PS1, which suggested that presenilins might be 
involved in vesicular routing, as mentioned in the Introduction. Additionally, the N-terminus of PS- 
1 was shown to bind to RabGDI which is a regulatory factor also involved in vesicular transport 
(Scheper et al., 2000). Furthermore, Scheper and co-workers have found that in fibroblasts Rab6 
membrane association is PKC dependent and that this regulation of Rab6 membrane association is 
dependent on PS-1 (Scheper et al., 2004).
Other isolated interaction partners include Ets variant gene 5 (ETV5), which encodes a Pea3 
subfamily ETS domain transcription factor. Recent results show that the Pea3 subfamily members 
play a role in epithelial-mesenchymal interactions during lung organogenesis (Liu et al., 2003).
Another interesting interaction partner is Ring Finger Protein 27 (RNF27) which was found to 
interact with PS-1. This is a protein motif related to the zinc finger motif, found on the sequence of 
the RING1 gene. This motif was later found in 27 proteins, all of which have putative DNA 
binding functions (Lovering et al., 1993). Protein DNA interactions are involved in many of the 
fundamental processes that occur inside cells for example, transcription and replication. To meet 
such a demand, a number of protein sequence or structural motifs have evolved to allow DNA 
interaction (Freemont et al., 1991; Harrison, 1991). This is interesting because it brings about the 
question of whether this protein actually interacted with PS-1, or if the presence of a DNA binding 
protein resulted in transcriprional activation without a protein-protein interaction. This was of 
course accounted for in the screening procedure, but RNF27 was only isolated once and found to 
interact with just PS-1, which makes it possible that was a false positive. However, presenilin is 
known to interact with a number of different proteins and to be involved in signaling processes 
therefore its interaction with RNF27 should not be ruled out.
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Lamin A/C which was isolated as a candidate interaction partner of PS-lAexon9. Nuclear lamins 
are filament proteins that were originally identified as components of the nuclear lamina (Aebi et 
al., 1986; McKeon et al., 1986). It was originally thought that the nuclear lamina functions to 
provide structural support and organisation to the nuclear envelope (Csoka et al., 2004; 
Lammerding et al., 2004; Lenz-Bohme et al., 1997; Newport et al., 1990; Smythe et al., 2000; 
Sullivan et al., 1999; Vigouroux et al., 2001), but recent findings have shown that lamins exist 
throughout the nucleoplasm suggesting a structural contribution to a nuclear matrix (Bridger et al., 
1993; Goldman et al., 1992; Hozak et al., 1995), and roles in DNA replication (Moir et al., 2000), 
transcription (Spann et al., 2002) and RNA processing (Jagatheesan et al., 1999; Kumaran et al., 
2002; Muralikrishna et al., 2001). Additionally, recent work in mouse and human ES cells has 
shown that lamin A/C is predominantly expressed in differentiated cells which suggests a role in 
the maintenance of a differentiated state (Constantinescu et al., 2005).
HS1 protein (hematopoetic lineage cell-specific protein 1) was isolated via its interaction with PS- 
1. It is a substrate for protein tyrosine kinases in lymphocytes, which binds to F-actin and promotes 
actin polymerization (Hao et al., 2005). Actin is associated with the plasma membrane where it 
triggers new behaviour in the cell when its environment changes, by membrane re-modelling to 
create tubules or vesicles (Revenu et al., 2004). As presenilin is also found in the plasma 
membrane, this supports a role for presenilin in vesicle formation.
Also, interestingly, a few of the hits obtained by the screening, were found to have chromosomal 
locations similar to factors thought to be involved in AD, or interaction partners of APP or the 
presenilins. This could have important implications. Such hits should be investigated further, to 
determine whether there is a link between chromosomal location, and a role in AD. Figure (5.7)
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shows "hits’ on chromosome 1 (same as PS-1, NicA and Aph-1) and chromosome 19 (same as 
ApoE)
I S p l lmi
1 9 * 15*1  -
1. 9 *1 5 . 2
1 9p 1 3.3 (T u b u lin -5 -b eta )  
1 9p 1 3.2 (R ab 3A )
19*13*9
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1 *25 —
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Figure (5.7) chromosomal map showing the chromosomal locations of some of the cDNA two-
hybrid hits.
According to the screening results, *he PS-2, Aph-1 and NicA genes are mapped to chromosome 1 in addition to 
LmnA, IFI16 and two new genes. ApoE is mapped to chromosome 19 in addition toTBB5 and Rab3A.
5.4.2.1 Evaluation o f  the screen results
Although the results o f the screening o f  the cDNA library are promising, caution should be taken 
when considering the results. False positives are a known problem with two-hybrid systems, and 
although using an E. coli two-hybrid system for detecting human protein interactions should result 
in fewer false positives observed, the system still does not completely rule them out, especially 
when such a large number o f  hits is obtained. Additionally, it is cause for concern that none of the 
proteins found in the literature to interact with PS-1 (e.g. Notch) and the now known y-secretase 
components, were isolated by this screening experiment. Furthermore, the cDNA library used from 
Stratagene is a commercial library, therefore we are not certain about its quality.
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Consequently, the degree of reliability o f the results obtained needs to be evaluated. A decision 
needs to be made about whether enough measures were taken while performing this experiment, to 
ensure only candidates that interact specifically with the bait proteins (PS-1 or PS-lAexon9 in this 
case) were seen as positive candidates. Also, a repeat of the experiment to ensure a higher level of 
specificity in the screening process should be considered. In addition, a great deal of research into 
the literature regarding what is known about the hits should be done to decide which of the hits 
obtained are significant enough to pursue further.
S.4.2.2 Future experiments
A new experiment, to determine the specificity of the screening procedure reported here can be 
performed. The cDNA library already isolated can be transformed into a reporter strain containing 
the bait plasmids as described. However, instead of Ampicillin plates, the transformants can be 
plated out on NZA plates containing Cm, Tet and Kan to ensure that all 3 plasmids are present in 
the strain, without exerting too much pressure on the cells to express the LacZ gene. The 
transformants should then be replicated onto indicator plates, where a positive protein-protein 
interaction produces a colour change.
Spiess et al., (1999) showed that DegP, the E. coli homologue of the human L56 had dual 
chaperone and protease activity at different temperatures. It was suspected that L56 may have a role 
in AD, and Christian Behrends (Diplom thesis, 2002) detected a positive protein-protein interaction 
between L56 and PS-1. Therefore, once the screening procedure is optimised, the E. coli two- 
hybrid system can be used to screen for interaction partners of L56 and an L56 mutant (L56SA), as 
well as other proteins known to interact with PS-1 or thought to have a role in AD.
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A large number of novel genes were isolated by the screening procedure, therefore these genes as 
well as others can be used for sequence homology to try and identify protein families (if any) that 
they might belong to, and then a speculation may be made about how and why these proteins 
interact with PS-1 and PS-lAexon9. Additionally, the cDNA library contains portions of genes 
therefore it may be informative to clone the full length genes of the candidate interaction partners 
of PS-1 and PS-lAexon 9 and repeat the entire procedure.
5.4.3 Conclusion
This chapter describes a convenient and simple system in E. coli for studying the complex 
interactions of human membrane proteins involved in AD, and those proteins thought to interact 
with members of the y-secretase complex. The system still needs to be optimised for each particular 
experiment, but the results so far are promising.
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6 GENERAL DISCUSSION
6.1 Alzheimer9s Disease (AD) to date
AD is a disease affecting the brain, and it is the most common neurodegenerative disease in the 
world. Nowadays, and especially in industrialised countries it is a major cause of death after heart 
diseases, stroke and cancer. Improved health care and a better standard of living in the west, 
resulted in an older average population age. Subsequently, as the risk of AD increases with age, this 
meant that AD has become a major problem in such countries. The disease causes a lot of 
emotional and physical strain to the patients and others around them, especially in the later stages. 
And in addition to the social implications o f the disease, the economic cost has started to cause a 
major problem in our societies. However, so far there is no definite diagnosis for AD and no 
current cure.
A few laboratories are investigating the chain of events which leads to AD pathology, and in 
particular the y-secretase pathway which causes proteolytic cleavage of C99, resulting in the 
production of Ap peptides which aggregate and form the amyloid plaques found in the brains of 
sufferers. However, to date all experiments in other laboratories, which were focused on the y- 
secretase complex have so far been performed in eukaryotic systems. We postulate that even 
though organisms like yeast may have no endogenous y-secretase activity, it is possible that other 
endogenous proteins could interact with PS-1, NicA, Pen-2 or Aph-1 and could aid the 
reconstitution of y-secretase activity in eukaryotes. However, to completely rule out the 
involvement of other factors in bringing about y-secretase activity, a simpler experimental system 
would be of use when analysing the complex. Here we describe the use of the gram negative 
bacteria E. coli to investigate the y-secretase pathway and to verify that PS-1, NicA, Pen-2 and 
Aph-1 are the minimal components required for an active y-secretase complex.
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6,2 E, coli as a model system for the investigation o f  y-secretase activity
The production of human membrane proteins in bacteria is still considered as very difficult as 
various problems are generally incurred during the process. These problems are not only relevant 
for high level production but also for basic structure/function analyses or for protein-protein 
interaction studies.
Difficulties in gene expression include degradation by E. coli proteases and mutations in the 
transformed plasmids. Therefore in this project we describe the use of suitable expression vectors 
such as pGDRll or pCS19, and a suitable E. coli strain such as KU98 (Chapter 3). An additional 
problem may be inclusion bodies that are the result of a high number of un- or not completely 
folded proteins in the cytoplasm. Folding of human proteins often requires a longer amount of time 
in E. coli. Consequently, aggregation of hydrophobic regions (such as TM-segments in polytopic 
membrane proteins e.g. PS-1 and Aph-1) leads to the formation of inclusion bodies that are often 
described as a result of attempts to over-express human genes in bacteria.
However we show that human membrane protein production is possible in E. coli. We describe 
how the simple system of E. coli can be used to produce human membrane proteins, determine their 
topology in the E. coli membrane and to analyse their protein-protein interactions. Heterologous 
expression has numerous advantages such as the absence of homologues and splice variants. The 
bacterial system also allows convenient modification and purification approaches.
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6.3 Components o f the y-secretase complex are successfully produced in E. coli
6.3.1 Expression studies of the y-secretase complex components, and the substrate C99
Chapter (3) of this thesis describes successful cloning of the genes encoding Pen-2 and Aph-1 from 
a cDNA library, and their subsequent expression in E. coli. Expression of both pen-2 and aph-1 
from the plasmids encoding them, pSAl and pS A ll for Pen-2; and pSA2 and pSA12 for Aph-1, 
resulted in the production of a high amount of each protein as verified by Western blotting (Figure 
3.3). Pen-2 was found to be stable after 4 hours and overnight induction while Aph-1 was stable 
after 4 hours of induction but was degraded overnight, presumably by E. coli proteases. 
Additionally despite initial suspicions, it seems that the presence of a His-tag fused to the N- 
terminus of Pen-2 does not affect the levels of expression of the protein, nor does it affect its 
topology. Therefore the plasmid pSA l, encoding Pen-2 with an N-terminal His-tag was used in all 
subsequent experiments as the presence of a His-tag was useful for the detection of protein 
expression and subsequent protein purification (Chapter 4).
It was thought that co-expression of ps-1 which encodes one of the y-secretase complex 
components, and c99 which encodes the y-secretase substrate may aid the stabilisation of Aph-1 
after overnight induction, but this was not found to be the case. Co-expression of ps-1 and c99 
(pSG33) with aph-1 (pSA2 and pSA12) did not stabilise Aph-1 overnight, nor did it increase the 
levels of Pen-2 or Aph-1 produced in the strain KU98. However, as we are uncertain about the 
sequence of events governing the assembly of the y-secretase complex or how the individual 
components interact with each other, it was thought that stabilisation of Aph-1 could possibly be 
achieved by co-expression of the of the genes encoding the other y-secretase components NicA, 
and Pen-2. Additionally, the PS-1 gain o f function mutant PSlAexon9 was found to be involved in 
FAD so the co-expression of pslAexon9  and c99 (pSG34) with either pen-2 or aph-1 may result in 
higher levels of expression of the genes and/or the stabilisation of Aph-1 overnight. A suggestion
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for a new experiment could be to combine the four y-secretase components, in the presence and 
absence of C99 in the same protease minus strain such as KU98 and to compare that to co­
expression of the four components in a number of strains containing different combinations of the 
y-secretase components. This was not possible to accomplish in this project as a result of the 
different antibiotic resistances conferred by the plasmids containing the y-secretase components’ 
genes, and the different origins o f replication. However, additional strains should be investigated 
and it is also a possibility to clone the genes encoding the y-secretase components into alternative 
plasmids. Such an experiment could result in an achievement of an even higher level of over­
expression for the y-secretase components. The individual or combination of proteins can then be 
used for purification studies and enzyme assays.This will also give us an insight into which of the 
y-secretase components directly interact with each other and the sequence of events leading to the 
y-secretase cleavage of C99. This will provide a very good and detailed sequence of events that can 
be targeted for drug design and future treatment o f AD.
Chapter (3) described the construction o f a plasmid containing pen-2 and aph-1 to aid the 
combination of all the y-secretase components in the same bacterial strain. We successfully cloned 
and expressed pen-2 and aph-1 in the plasmid pG R D ll (pSA13 and pSA14) (Figure 3.5). The 
production of Pen-2 and Aph-1 in the strain KU98 was detected by incubating the PVDF 
membrane containing both proteins with a monoclonal a-penta histidine antibody (Qiagen). The 
purification of Pen-2 in chapter (4) has revealed that pure Pen-2 can form dimers. The pen-2 dimer 
migrates at roughly the same molecular weight as an Aph-1 monomer (25 kDa), therefore in 
hindsight we are aware that using the a-penta histidine antibody for the detection of both proteins 
present on the same membrane is not advisable, as it could be very difficult to differentiate between 
an Aph-1 monomer and a Pen-2 dimer. However, at the time of the experiment there was no 
alternative antibody that could have been used for the detection of Aph-1. Additionally, Pen-2 has
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only been shown to form dimers when purified, or very rarely when expressed in very high 
amounts and the SDS gels are overloaded. Such behaviour was also observed during over­
expression and purification of the y-secretase complex substrate C99. Furthermore, even if the band 
at 25 kDa (Figure 3.5) represented Pen-2, this does not rule out the possibility that Aph-1 is also 
expressed but at very low levels and that it is migrating at the same molecular weight.
6.3.2 Topological Studies
Chapter (3) described how the well established method of phoA fusions was used to ensure that the 
human y-secretase components expressed in E. coli (Manoil and Beckwith, 1986) have the correct 
topology because that is essential for their function. Previous work (Fortna et al., 2004) has shown 
that Aph-1 spans the membrane seven times. However, according to the amino acid sequence of 
Aph-1, it was predicted that the protein will have six transmembrane segements (Kyle and 
Doolittle, 1982). This work has supported this prediction by expression studies and the 
performance of PhoA assays. Additionally, Pen-2 was found to span the bacterial membrane twice, 
which is what was predicted from its amino acid sequence.
6.3.3 Purification studies and mass spectrometry
Chapter (4) of this thesis describes successful purification of Pen-2 via FPLC by using its N- 
terminal His-tag. The purity of the Pen-2 produced was ascertained by loading the pure protein onto 
a Shaegger gel and subsequently Coomassie staining to check for the lack of other proteins, and 
Western blotting with a polyclonal a-Pen-2 antibody to check that all bands seen represented Pen-2. 
Mass spectrometric studies on pure Pen-2 should be performed to check the protein’s exact 
molecular mass, and to determine if it has undergone any post-translational modifications in 
bacteria. Other uses for pure Pen-2 could be the production of polyclonal antibodies directed
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specifically against Pen-2 which would be useful for future work involving this protein 
investigating, for example, the y-secretase complex or the interaction of Pen-2 with other proteins.
This chapter also describes the purification of Pen-2 from whole cell extract. This could be a 
disadvantage because it means that any Pen-2 that was not properly translocated to the bacterial 
membrane was also purified. However, figure (4.1) shows that most of the Pen-2 was located in the 
membrane. However, the purification of pen-2 from membranes was not possible when attempted 
in this case. Thus, some thought should be invested into how membranes of Pen-2 could be 
prepared and the protein purification performed with the least amount of protein loss possible. On 
the other hand, the purification scheme employed here is probably unproblematic as the small Pen- 
2 protein lacks a complex tertiary structure. After the dilution of detergent, Pen-2 should be well 
able to fold into its proper conformation.
Figure (4.4) shows Pen-2 obtained as a result of purification by FPLC. In addition to the protein 
migrating at the correct molecular weight of approximately 12 kDa, other bands were observed that 
could be oligomers of Pen-2. This behaviour was also seen with C99. However, as the bands are 
undefined and migrate as a smear there is also a possibility that they could be aggregates of Pen-2 
and that pen-2 shows similar behaviour to PS-1 when a large amount of protein is loaded onto a gel 
(Mona Hamasch, PhD Thesis, 2003).
Co-purification studies of C99 and PS-1 have indicated that the two proteins interact (Hamasch et 
al., 2004). To investigate the interaction of the other y-secretase components, or interactions 
between the y-secretase components and the substrate C99, additional co-purification experiments 
could be performed. An example is the use of the plasmid pSA16 which encodes Pen-2 without a 
tag and Aph-1 with an N-terminal His-tag. The His-tag could be used to purify Aph-1 with a Ni
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NTA column, and it would be interesting to see if Pen-2 will co-purify. This experiment would give 
us an insight into a possible interaction between the y-secretase components Pen-2 and Aph-1.
6.4 An investigation into the activity o f the y-secretase complex in E. coli
6.4.1 y-Secretase Assays and Ap ELISA
An attempt at reconstituting y-secretase activity in E. coli in initial assays was described in chapter 
(4). Two experiments were carried out. The first involved co-expression of ps-1, c99, pen-2, aph-1 
and nicA in one E. coli strain, KS272 whereas the second assay involved the expression of the 
genes encoding the individual components in the strain KU98 separately and subsequently mixing 
the membranes containing the y-secretase components.
It seems that the co-expression experiment was more successful at reconstituting y-secretase 
activity, compared to the experiment involving the mixing of bacterial membranes containing the y- 
secretase components. The first experiment resulted in higher y-secretase activity and lower 
background levels. However, the second assay should not be completely excluded as perhaps a 
combination of the two could be achieved. For example, the y-secretase components could be 
purified individually or in combinations, and subsequently the pure proteins could be mixed 
together. Additionally, because the Ap ELISA is carried out on a 96-well plate, various conditions 
could be conveniently tested for their effect on the y-secretase activity measured. Different 
detergents could be used to solubilise the y-secretase components from membranes, the assay could 
be carried out in various concentrations of salts and different pH values. Despite the fact that the 
ELISA detected relatively low levels of Ap, the amounts still correlated with what is so far 
published in the literature (Fraering et al., 2004).
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6.4.2 The E. coli two-hybrid system unveils interactions between y-secretase 
components and isolates candidate interaction partners of PS-1 and PS-lAexon9
Recent studies have identified the gene products that comprise the y-secretase and established their 
physical interaction is required for y-secretase activity. It was previously shown that under non­
denaturing conditions, the y-secretase is associated with a molecular mass which corresponds to the 
combined apparent molecular mass of PS, NicA, Pen-2 and Aph-1 (Kimberly et al., 2003). 
However, little is known about their specific roles in intramembrane proteolysis or the nature of the 
individual protein-protein interactions within the active complex. Additionally, any information 
regarding the interaction between different y-secretase components will give us insight into the 
structural organisation of the active y-secretase complex. This is essential for determining the 
biochemistry of the y-secretase complex involved in the processing of Notch and several other type 
I transmembrane proteins, most importantly for us, APP.
It was established by Dove and co-workers (1997) that any protein-protein interaction can activate 
transcription in E. coli provided one protein of interest is bound to the DNA via a DNA binding 
domain (e.g. Xcl), and the other protein of interest is bound to a subunit of RNA polymerase. 
Previous work in this laboratory where PS-1 was fused to the A,cl and C99 was fused to the co 
subunit of RNAP, showed that the two proteins interact in an E. coli two-hybrid system (Hamasch 
et al., 2004). It was then interesting to see if other y-secretase components interacted which would 
help us build a picture of how the y-secretase cleavage step takes place and the sequence of events 
involved.
Firstly, to analyse interactions between the known y-secretase components, a number of gene 
fusions were generated (Chapter 5). aph-1 was fused to the co subunit of RNAP and the A,cl ; and 
nicA was fused to the co subunit of RNAP. Successful cloning of the genes into appropriate
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expression vectors is described. However, although expression of the gene fusions was not 
optimised, p-galactosidase assays indicated not only that the protein fusions were produced, but 
also that members of the y-secretase complex interact with each other. The results indicated that 
Aph-1 interacts with PS-1 and NicA but not with C99 and that NicA interacts with PS-1, which 
correlates with the literature (see next paragraph).
The PS heterodimer is thought to be the active form of the protein (Capell et al., 1998; Podlisny et 
al., 1997; Thinakaran et al., 1996; Yu et al., 1998). All presenilins contain two conserved 
intramembraneous active site residues, the mutation of which reduces Ap secretion and PS 
endoproteolysis. This together with the fact that y-secretase inhibitors can be covalently linked to 
PS1 NTF and CTF (Esler et al., 2000; Li et al., 2000a), suggests that PS NTF/CTF heterodimer 
comprise the active site of y-secretase. Furthermore, co-immunoprecipitation experiments in 
multiple cell lines using antibodies against Aph-1 reveal a selective association between Aph-1 and 
NicA. This shows that Aph-1 and NicA directly interact early in the y-secretase assembly, forming 
a stable intermediate prior to the incorporation o f PS and Pen-2, PS endoproteolysis and the final 
glycosylation of NicA all of which are known to correlate with mature, active y-secretase (LaVoie 
et al., 2003). Fraering and co-workers have shown that the detergent DDM can dissociate active y- 
secretase complexes in a concentration dependent manner into two major complexes (mature NicA 
and Aph-1, Pen-2 and PS-1-NTF; and two minor complexes NicA, Aph-1 and PS-1-CTF; and PS- 
1CTF and PS-1 NTF. This is likely to reflect the physical interactions that exist in the active y- 
secretase complex (figure 6.1).
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Figure (6.1) Schematic representation of the subunit organization within the active "y-secretase
complex.
This model is based on the protein-protein interactions identified in the complexes generated by the DDM-mediated 
dissociation of'V-secretase: Pen-2 interacts directly with PS1-NTF, mNicA (Here NCT) interacts directly with Aphl, 
PS 1-CTF interacts directly with PS 1-NTF, and PS 1-CTF interacts with NicA and Aphl. Taken from Fraering et al 
(2003).
Evidence suggests that Aph-1 stabilises the complex while Pen-2 is required for endoproteolytic 
processing of PS-1 in mammalian cells (Luo et al., 2003; Takasugi et al., 2003) and in yeast 
(Edbauer et al., 2003). Because proper trafficking and compartmentalization of all four these 
proteins as well as full glycosylation of NicA are essential for formation of functional y-secretase 
complex, Baulac and co-workers analysed the interactions of these newly identified members using 
immunofluorescence microscopy in Chinese hamster ovary (CHO) cells stably expressing the 
human proteins. They report that all four proteins interact in the Golgi/Zram-Golgi network (TGN)- 
enriched compartments where they observe y-secretase cleavage of APP C-terminal fragments 
(C99, C89, C83) and generation of Ap and AICD. Immunofluorescence studies provide evidence 
for the localisation of the components in the Golgi/TGN compartments rather than in the ER 
(Baulac et al., 2003).
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Work on this project has also shown that the E. coli two-hybrid system can be utilised to screen for 
candidate interaction partners of the active site protein in the y-secretase complex, PS-1; and the 
gain of function mutant PS-lAexon9, in a human foetal neuronal cDNA library. A few interaction 
partners were successfully isolated which all point towards a role for PS-1 in many various 
processes (Chapter 5). The system still requires a great deal of optimisation, but the results so far 
are promising. For example, RAB3A was found to interact with PS-1 which correlates with 
information in the literature. In addition, the isolated interaction partners await further 
investigation.
6.5 Conclusion
This thesis shows that E. coli represent a simple and efficient system that can be used to analyse 
human membrane proteins. Components of the y-secretase complex were successfully cloned and 
expressed in E. coli and their topologies in the bacterial membrane were studied using phoA 
fusions. Furthermore, interactions of the y-secretase complex components were investigated using 
the E. coli two-hybrid system, and intitial studies to reconstitute y-secretase activity using the 
components produced in E. coli were carried out. This was an interesting project, which opened up 
many possibilities for the study of the y-secretase complex in E. coli and presented potential targets 
and strategies for the treatment of Alzheimer’s disease. For example, convenient production of the 
active y-secretase complex could improve high throughput screens for y-secretase inhibitors or 
small molecules interfering with y-secretase complex assembly.
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